<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Antiretroviral resistance testing in HIV‐positive people - Aves, T - 2018 | Cochrane Library</title> <meta content="Antiretroviral resistance testing in HIV‐positive people - Aves, T - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006495.pub5/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Antiretroviral resistance testing in HIV‐positive people - Aves, T - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006495.pub5/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD006495.pub5" name="dc.identifier" scheme="DOI"/> <meta content="Antiretroviral resistance testing in HIV‐positive people" name="citation_title"/> <meta content="Theresa Aves&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="McMaster University" name="citation_author_institution"/> <meta content="Joshua Tambe&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="Yaoundé Central Hospital" name="citation_author_institution"/> <meta content="Reed AC Siemieniuk" name="citation_author"/> <meta content="McMaster University" name="citation_author_institution"/> <meta content="Lawrence Mbuagbaw" name="citation_author"/> <meta content="mbuagblc@mcmaster.ca" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="11" name="citation_issue"/> <meta content="10.1002/14651858.CD006495.pub5" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/11/09" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006495.pub5/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006495.pub5/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006495.pub5/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Drug Resistance, Viral; Antirheumatic Agents [adverse effects, *therapeutic use]; CD4 Lymphocyte Count; Disease Progression; HIV Seropositivity [*drug therapy, mortality, virology]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <meta content="" name="citation_fulltext_world_readable"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006495.pub5&amp;doi=10.1002/14651858.CD006495.pub5&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006495.pub5&amp;doi=10.1002/14651858.CD006495.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006495.pub5&amp;doi=10.1002/14651858.CD006495.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006495.pub5&amp;doi=10.1002/14651858.CD006495.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006495.pub5&amp;doi=10.1002/14651858.CD006495.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006495.pub5&amp;doi=10.1002/14651858.CD006495.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006495.pub5&amp;doi=10.1002/14651858.CD006495.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006495.pub5&amp;doi=10.1002/14651858.CD006495.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006495.pub5&amp;doi=10.1002/14651858.CD006495.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006495.pub5&amp;doi=10.1002/14651858.CD006495.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006495.pub5&amp;doi=10.1002/14651858.CD006495.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006495.pub5&amp;doi=10.1002/14651858.CD006495.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006495.pub5&amp;doi=10.1002/14651858.CD006495.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006495.pub5&amp;doi=10.1002/14651858.CD006495.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006495.pub5&amp;doi=10.1002/14651858.CD006495.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006495.pub5&amp;doi=10.1002/14651858.CD006495.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006495.pub5&amp;doi=10.1002/14651858.CD006495.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006495.pub5&amp;doi=10.1002/14651858.CD006495.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006495.pub5&amp;doi=10.1002/14651858.CD006495.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006495.pub5&amp;doi=10.1002/14651858.CD006495.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006495.pub5&amp;doi=10.1002/14651858.CD006495.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006495.pub5&amp;doi=10.1002/14651858.CD006495.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006495.pub5&amp;doi=10.1002/14651858.CD006495.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="IregKd2C";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD006495\x2epub5\x26doi\x3d10\x2e1002\x2f14651858\x2eCD006495\x2epub5\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006495\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006495\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ru","ms","fr","fa"],languageCode:"en",accessStatus:"open-access",doi:"10.1002/14651858.CD006495.pub5",title:"Antiretroviral resistance testing in HIV\\u2010positive people",firstPublishedDate:"Nov 9, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Infectious Diseases Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=IregKd2C&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006495.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006495.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD006495.pub5/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD006495.pub5/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006495.pub5%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD006495.PUB5" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD006495.pub5/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD006495.PUB5" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD006495.pub5/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD006495.pub5/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5093 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD006495.pub5" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006495.pub5/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006495.pub5/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006495.pub5/full#CD006495-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006495.pub5/full#CD006495-sec-0114"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006495.pub5/full#CD006495-sec-0030"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006495.pub5/full#CD006495-sec-0031"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006495.pub5/full#CD006495-sec-0036"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006495.pub5/full#CD006495-sec-0037"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006495.pub5/full#CD006495-sec-0072"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006495.pub5/full#CD006495-sec-0108"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006495.pub5/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006495.pub5/appendices#CD006495-sec-0119"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006495.pub5/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006495.pub5/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/table_n/CD006495StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/table_n/CD006495StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006495.pub5/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006495.pub5/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006495.pub5/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006495.pub5/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006495.pub5/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD006495.pub5/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley &amp; Sons, Ltd. on behalf of The Cochrane Collaboration." data-creative-commons="true" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Antiretroviral resistance testing in HIV‐positive people</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author custom-tooltip" title="These authors contributed equally to this work"><a href="/cdsr/doi/10.1002/14651858.CD006495.pub5/information#CD006495-cr-0002">Theresa Aves</a><sup>a</sup></li> <li class="author custom-tooltip" title="These authors contributed equally to this work"><a href="/cdsr/doi/10.1002/14651858.CD006495.pub5/information#CD006495-cr-0003">Joshua Tambe</a><sup>a</sup></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006495.pub5/information#CD006495-cr-0004">Reed AC Siemieniuk</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006495.pub5/information#CD006495-cr-0005"><i class="icon corresponding-author fa fa-envelope"></i>Lawrence Mbuagbaw</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/information/en#CD006495-sec-0125">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 09 November 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD006495.pub5">https://doi.org/10.1002/14651858.CD006495.pub5</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD006495-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006495-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006495-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006495-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD006495-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD006495-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD006495-abs-0001" lang="en"> <section id="CD006495-sec-0001"> <h3 class="title" id="CD006495-sec-0001">Background</h3> <p>Resistance to antiretroviral therapy (ART) among people living with human immunodeficiency virus (HIV) compromises treatment effectiveness, often leading to virological failure and mortality. Antiretroviral drug resistance tests may be used at the time of initiation of therapy, or when treatment failure occurs, to inform the choice of ART regimen. Resistance tests (genotypic or phenotypic) are widely used in high‐income countries, but not in resource‐limited settings. This systematic review summarizes the relative merits of resistance testing in treatment‐naive and treatment‐exposed people living with HIV. </p> </section> <section id="CD006495-sec-0002"> <h3 class="title" id="CD006495-sec-0002">Objectives</h3> <p>To evaluate the effectiveness of antiretroviral resistance testing (genotypic or phenotypic) in reducing mortality and morbidity in HIV‐positive people. </p> </section> <section id="CD006495-sec-0003"> <h3 class="title" id="CD006495-sec-0003">Search methods</h3> <p>We attempted to identify all relevant studies, regardless of language or publication status, through searches of electronic databases and conference proceedings up to 26 January 2018. We searched MEDLINE, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL), in the Cochrane Library, the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP), and ClinicalTrials.gov to 26 January 2018. We searched Latin American and Caribbean Health Sciences Literature (LILACS) and the Web of Science for publications from 1996 to 26 January 2018. </p> </section> <section id="CD006495-sec-0004"> <h3 class="title" id="CD006495-sec-0004">Selection criteria</h3> <p>We included all randomized controlled trials (RCTs) and observational studies that compared resistance testing to no resistance testing in people with HIV irrespective of their exposure to ART. </p> <p>Primary outcomes of interest were mortality and virological failure. Secondary outcomes were change in mean CD4‐T‐lymphocyte count, clinical progression to AIDS, development of a second or new opportunistic infection, change in viral load, and quality of life. </p> </section> <section id="CD006495-sec-0005"> <h3 class="title" id="CD006495-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed each reference for prespecified inclusion criteria. Two review authors then independently extracted data from each included study using a standardized data extraction form. We analysed data on an intention‐to‐treat basis using a random‐effects model. We performed subgroup analyses for the type of resistance test used (phenotypic or genotypic), use of expert advice to interpret resistance tests, and age (children and adolescents versus adults). We followed standard Cochrane methodological procedures. </p> </section> <section id="CD006495-sec-0006"> <h3 class="title" id="CD006495-sec-0006">Main results</h3> <p>Eleven RCTs (published between 1999 and 2006), which included 2531 participants, met our inclusion criteria. All of these trials exclusively enrolled patients who had previous exposure to ART. We found no observational studies. Length of follow‐up time, study settings, and types of resistance testing varied greatly. Follow‐up ranged from 12 to 150 weeks. All studies were conducted in Europe, USA, or South America. Seven studies used genotypic testing, two used phenotypic testing, and two used both phenotypic and genotypic testing. Only one study was funded by a manufacturer of resistance tests. </p> <p>Resistance testing made little or no difference in mortality (odds ratio (OR) 0.89, 95% confidence interval (CI) 0.36 to 2.22; 5 trials, 1140 participants; moderate‐certainty evidence), and may have slightly reduced the number of people with virological failure (OR 0.70, 95% CI 0.56 to 0.87; 10 trials, 1728 participants; low‐certainty evidence); and probably made little or no difference in change in CD4 cell count (mean difference (MD) ‐1.00 cells/mm³, 95% CI ‐12.49 to 10.50; 7 trials, 1349 participants; moderate‐certainty evidence) or progression to AIDS (OR 0.64, 95% CI 0.31 to 1.29; 3 trials, 809 participants; moderate‐certainty evidence). Resistance testing made little or no difference in adverse events (OR 0.89, 95% CI 0.51 to 1.55; 4 trials, 808 participants; low‐certainty evidence) and probably reduced viral load (MD ‐0.23, 95% CI ‐0.35 to ‐0.11; 10 trials, 1837 participants; moderate‐certainty evidence). No studies reported on development of new opportunistic infections or quality of life. We found no statistically significant heterogeneity for any outcomes, and the I² statistic value ranged from 0 to 25%. We found no subgroup effects for types of resistance testing (genotypic versus phenotypic), the addition of expert advice to interpretation of resistance tests, or age. Results for mortality were consistent when we compared studies at high or unclear risk of bias versus studies at low risk of bias. </p> </section> <section id="CD006495-sec-0007"> <h3 class="title" id="CD006495-sec-0007">Authors' conclusions</h3> <p>Resistance testing probably improved virological outcomes in people who have had virological failure in trials conducted 12 or more years ago. We found no evidence in treatment‐naive people. Resistance testing did not demonstrate important patient benefits in terms of risk of death or progression to AIDS. The trials included very few participants from low‐ and middle‐income countries. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD006495-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006495-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006495-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006495-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD006495-abs-0009">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD006495-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD006495-abs-0007">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD006495-abs-0006">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD006495-abs-0005" lang="en"> <h3>Antiretroviral resistance testing in people living with HIV</h3> <p><b>What is the aim of this review?</b> </p> <p>The aim of this review was to find out whether a drug resistance test for people living with HIV (starting antiretroviral therapy (ART) or already on ART but with unsuppressed HIV) would reduce the number of deaths or improve HIV suppression. </p> <p><b>Background</b> </p> <p>Drug resistance to ART implies that specific antiretroviral drugs will be less effective. This happens either because the virus has changed to become resistant, or because an individual was infected with a resistant virus. To determine which drugs will be less effective, healthcare providers may conduct a resistance test. Two kinds of resistance tests are available: the genotypic test, in which the virus is examined to determine which drugs it is resistant to, and the phenotypic test, in which the virus is exposed to antiretroviral drugs to see which one it is resistant to. Use of resistance tests is common only in high‐income countries. Before we prepared this review, we did not know how well the use of resistance tests may reduce the number of deaths and improve HIV suppression. </p> <p><b>Main results</b> </p> <p>Cochrane review authors collected and analysed all relevant studies up to 26 January 2018 to answer this question and included 11 randomized controlled trials (published between 1999 and 2006) with a total of 2531 people. Trials included only people who had detectable HIV despite being on antiretroviral drugs; no trials included patients starting therapy for the first time. Studies were conducted in Europe, USA, or South America. Seven studies used genotypic testing, two used phenotypic testing, and two used both phenotypic and genotypic testing. Only one study was funded by a manufacturer of resistance tests. </p> <p>Resistance testing probably made little or no difference to the risk of dying (moderate‐certainty evidence) or progression to AIDS (moderate‐certainty evidence). Resistance testing probably increased the chance of successful suppression of HIV replication (low‐certainty evidence) but probably made little or no difference in CD4 cell counts (cells affected by HIV) (moderate‐certainty evidence). Resistance testing made little or no difference in the number of people who experience medication side effects (low‐certainty evidence). No studies examined how many people developed a new opportunistic infection, and no studies examined patient quality of life. </p> <p><b>Conclusion</b> </p> <p>For people for whom treatment no longer works, the use of resistance tests to select new treatments led to suppression of the HIV virus as measured by a blood test, but probably did not reduce the risk of death or progression to AIDS. Whether or not resistance testing provides any benefit for patients who are starting HIV treatment for the first time remains uncertain because no studies have evaluated this. These conclusions are based on studies conducted up to 12 years ago and included very few participants from low‐ and middle‐income countries. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD006495-sec-0114" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD006495-sec-0114"></div> <h3 class="title" id="CD006495-sec-0115">Implications for practice</h3> <section id="CD006495-sec-0115"> <p>Resistance testing probably provides virological benefits (measured up to six months) for people who are experiencing failing therapy and switching to a non‐integrase inhibitor‐based antiretroviral therapy (ART) regimen. American and European guidelines already recommend HIV resistance testing for these patients (<a href="./references#CD006495-bbs2-0047" title="European AIDS Clinical Society. Guidelines 2017. www.eacsociety.org/files/guidelines_9.0‐english.pdf (accessed 2 August 2018). ">EACS 2017</a>; <a href="./references#CD006495-bbs2-0071" title="SaagMS , BensonCA , GandhiRT , HoyJF , LandovitzRJ , MugaveroMJ , et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society‐USA Panel. JAMA2018;320(4):379‐96. [PUBMED: 30043070] ">Saag 2018</a>). Even though these guidelines also recommend resistance testing in treatment‐naive people, we found no trials that included treatment‐naive people. However, inferences on how resistance testing will perform in treatment‐naive people can be drawn from these findings and from other systematic reviews demonstrating that the odds of virological failure were higher when HIV‐positive people with transmitted drug resistance (TDR) were started on ART without resistance testing (odds ratio (OR) 2.96, 95% CI 1.89 to 4.65; 12 observational studies; <a href="./references#CD006495-bbs2-0085" title="World Health Organization. Guidelines on the Public Health Response to Pretreatment HIV Drug Resistance. http://apps.who.int/iris/bitstream/handle/10665/255880/9789241550055‐eng.pdf?sequence=1 (accessed 25 July 2018). ">WHO 2017a</a>). Another observational study reported improved survival among treatment‐experienced patients (hazard ratio (HR) 0.70, 95% CI 0.51 to 0.96) but not in treatment‐naive patients (HR 0.25, 95% CI 0.03 to 1.82) when resistance testing was used (<a href="./references#CD006495-bbs2-0061" title="PalellaFJJr , ArmonC , BuchaczK , ColeSR , ChmielJS , NovakRM , et al. The association of HIV susceptibility testing with survival among HIV‐infected patients receiving antiretroviral therapy: a cohort study. Annals of Internal Medicine2009;151(2):73‐84. [PUBMED: 19620160] ">Palella 2009</a>). It is unclear if the benefits of testing may be greater for treatment‐naive patients, who would have more therapeutic options. However, the costs of resistance testing and the feasibility of widespread rollout in resource‐limited settings must be considered. </p> </section> <h3 class="title" id="CD006495-sec-0116">Implications for research</h3> <section id="CD006495-sec-0116"> <p>Although additional trials would provide a more robust body of evidence, they are unlikely to be conducted, given that resistance testing after initiation of treatment and after treatment failure is already performed as part of routine care in some parts of the world. The major downside of this testing appears to involve costs and feasibility, as resistance testing is unlikely to cause harm. In treatment‐naive people, investigators should consider the ethical implications of randomizing participants to a "no resistance testing" arm, as well as the best strategies for incorporating other factors along the cascade of care that influence outcomes such as adherence to medication and potency of ART regimens. Studies using a non‐randomized design and administrative databases may provide answers to these questions. </p> <p>Based on the findings of this review, we recommend further investigation of the role of resistance testing in treatment‐naive people with HIV and in subpopulations with a greater incidence of TDR, such as men who have sex with men (MSM), commercial sex workers (CSWs), and people who inject drugs (PWIDs). Those conducting randomized investigations should consider use of "delayed resistance testing" instead of "no resistance testing". Mortality is an important outcome that future studies are encouraged to report, in addition to virological outcomes and quality of life. However, resistance testing is unlikely to lead to reduced mortality in the short term ‐ longer‐term large studies would be needed to enhance our understanding of whether improvement in the surrogate measure (viral load) leads to improvements in outcomes that patients are likely to consider important, such as mortality. We also recommend that studies be conducted in low‐resource settings. Given the prohibitive costs of resistance testing, which preclude its widespread use, economic analyses are imperative for low‐income settings before such testing is widely adopted in these places. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD006495-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD006495-sec-0030"></div> <div class="table" id="CD006495-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Resistance testing versus no resistance testing in HIV‐positive people</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Resistance testing versus no resistance testing in HIV‐positive people</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> HIV‐positive people<br/> <b>Setting:</b> all settings<br/> <b>Intervention:</b> resistance testing<br/> <b>Comparison:</b> no resistance testing </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (trials)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no resistance testing</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with resistance testing</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mortality</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.89<br/> (0.36 to 2.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1140<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a,b,c</sup> </p> <p><i>Due to imprecision</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Resistance testing probably has little or no impact on mortality</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000<br/> (8 to 47) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Virological failure</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.70<br/> (0.56 to 0.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1728<br/> (10 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,d,e,f</sup> </p> <p><i>Due to risk of bias and publication bias</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Resistance testing may reduce the risk of virological failure</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>660 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>576 per 1000<br/> (521 to 628) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in CD4 cell count</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change in CD4 cell count was 0.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1 lower<br/> (12.49 lower to 10.5 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1349<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a,d</sup> </p> <p><i>Due to risk of bias</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Resistance testing probably has little or no effect on change in CD4 cell count</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Progression to AIDS</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.64<br/> (0.31 to 1.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>809<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>g</sup> </p> <p><i>Due to indirectness</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Resistance testing probably has little or no impact on progression to AIDS</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>67 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>44 per 1000<br/> (22 to 85) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.89<br/> (0.51 to 1.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>808<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>h,i</sup> </p> <p><i>Due to risk of bias and indirectness</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Resistance testing may have little or no effect on adverse effects</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>74 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>66 per 1000<br/> (39 to 110) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in viral load</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change in viral load was 0.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.23 lower<br/> (0.35 lower to 0.11 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1837<br/> (10 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a,j</sup> </p> <p><i>Due to risk of bias</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Resistance testing probably results in a lower viral load</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>New opportunistic infection ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> Abbreviations: CI: confidence interval; MD: mean difference; OR: odds ratio; RCT: randomized controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Risk of bias: all studies included for this outcome were not blinded, but we did not downgrade for this, as lack of blinding is unlikely to introduce bias.<br/> <sup>b</sup>Risk of bias: one included study was at high risk of bias overall, but it contributed 16.1% of the data (<a href="./references#CD006495-bbs2-0011" title="WegnerSA , WallaceMR , AronsonNE , TaskerSA , BlazesDL , TammingaC , et al. Long‐term efficacy of routine access to antiretroviral‐resistance testing in HIV type 1‐infected patients: results of the clinical efficacy of resistance testing trial. Clinical Infectious Diseases2004;38(5):723‐30. [PUBMED: 14986258] ">Wegner 2004</a>). We did not downgrade for this.<br/> <sup>c</sup>Downgraded by 1 for imprecision: CIs for the odds ratio include considerable harm and considerable benefit. We downgraded one point for this.<br/> <sup>d</sup>Downgraded by 1 for risk of bias: four of the included studies (˜ 37% of data) were at high or unclear risk of bias (<a href="./references#CD006495-bbs2-0002" title="CingolaniA , AntinoriA , RizzoMG , MurriR , AmmassariA , BaldiniF , et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS (London, England)2002;16(3):369‐79. [PUBMED: 11834948] ">Cingolani 2002;</a><a href="./references#CD006495-bbs2-0003" title="CohenCJ , HuntS , SensionM , FarthingC , ConantM , JacobsonS , et al. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS (London, England)2002;16(4):579‐88. [PUBMED: 11873001] ">Cohen 2002;</a><a href="./references#CD006495-bbs2-0007" title="HaubrichRH , KemperCA , HellmannNS , KeiserPH , WittMD , TillesJG , et al. A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575. AIDS (London, England)2005;19(3):295‐302. [PUBMED: 15718840] ">Haubrich 2005;</a><a href="./references#CD006495-bbs2-0009" title="RubiniNPM , BrindeiroPA , BrindeiroRM , LlerenaCA , HertogsK , TanuriA . Clinical value of HIV‐1 genotyping in children and adolescents heavily experiences in antiretroviral therapy. XIV International AIDS Conference. Barcelona, 2002. ">Rubini 2002</a>).<br/> <sup>e</sup>Indirectness: the included studies used different cutoffs to define virological failure. We did not downgrade for this.<br/> <sup>f</sup>Downgraded by 1 for publication bias: based on funnel plot asymmetry and a positive Egger's test.<br/> <sup>g</sup>Downgraded by 1 for indirectness: "progression to AIDS" was not defined uniformly across studies.<br/> <sup>h</sup>Downgraded by 1 for risk of bias: all studies included for this outcome were not blinded and adverse events could be interpreted subjectively.<br/> <sup>i</sup>Downgraded by 1 for indirectness: "adverse event" was not defined uniformly across studies. We downgraded one point for this.<br/> <sup>j</sup>Downgraded by 1 for risk of bias: four of the included studies (˜ 34% of data) were at high or unclear risk of bias (<a href="./references#CD006495-bbs2-0002" title="CingolaniA , AntinoriA , RizzoMG , MurriR , AmmassariA , BaldiniF , et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS (London, England)2002;16(3):369‐79. [PUBMED: 11834948] ">Cingolani 2002;</a><a href="./references#CD006495-bbs2-0003" title="CohenCJ , HuntS , SensionM , FarthingC , ConantM , JacobsonS , et al. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS (London, England)2002;16(4):579‐88. [PUBMED: 11873001] ">Cohen 2002;</a><a href="./references#CD006495-bbs2-0007" title="HaubrichRH , KemperCA , HellmannNS , KeiserPH , WittMD , TillesJG , et al. A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575. AIDS (London, England)2005;19(3):295‐302. [PUBMED: 15718840] ">Haubrich 2005;</a><a href="./references#CD006495-bbs2-0009" title="RubiniNPM , BrindeiroPA , BrindeiroRM , LlerenaCA , HertogsK , TanuriA . Clinical value of HIV‐1 genotyping in children and adolescents heavily experiences in antiretroviral therapy. XIV International AIDS Conference. Barcelona, 2002. ">Rubini 2002</a>). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD006495-sec-0031" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD006495-sec-0031"></div> <section id="CD006495-sec-0032"> <h3 class="title" id="CD006495-sec-0032">Description of the condition</h3> <p>Almost 36.7 million people are living with human immunodeficiency virus (HIV) worldwide (<a href="./references#CD006495-bbs2-0080" title="UNAIDS . Get on the Fast‐Track. The Life‐Cycle Approach to HIV. Finding Solutions for Everyone at Every Stage of Life. 2016. www.unaids.org/sites/default/files/media_asset/Get‐on‐the‐Fast‐Track_en.pdf (accessed 3 June 2017). ">UNAIDS 2016</a>). Widespread use of antiretroviral therapy (ART) has reduced the mortality and morbidity associated with HIV infection. Although only 40% of those eligible for ART are currently receiving it, efforts are under way to improve access to ART (<a href="./references#CD006495-bbs2-0084" title="World Health Organization. Antiretroviral Therapy (ART) Coverage Among All Age Groups. www.who.int/gho/hiv/epidemic_response/ART_text/en/ (accessed 3 June 2017). ">WHO 2017</a>). Effective ART inhibits viral replication and reduces viral load. The World Health Organization (WHO) Model List of Essential Medicines contains a list of antiretroviral drugs that are grouped into four classes: nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), non‐nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), and integrase strand transfer inhibitors (INSTIs; <a href="./references#CD006495-bbs2-0086" title="World Health Organization. 20th WHO Model List of Essential Medicines. http://www.who.int/medicines/publications/essentialmedicines/20th_EML2017_FINAL_amendedAug2017.pdf?ua=1 (accessed 24 April 2018). ">WHO 2017b</a>). Recommendations on how they should be used include consideration of cost, availability, ease of administration, toxicity, and efficacy (<a href="./references#CD006495-bbs2-0083" title="World Health Organization. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection. Recommendations for a Public Health Approach. Second Edition. June 2016. www.who.int/hiv/pub/arv/arv‐2016/en/ (accessed 3 June 2017). ">WHO 2016</a>). The potency of these medications can be severely compromised in the presence of drug resistance. In addition, the combination of drugs prescribed should be chosen with care, given that in some classes of antiretroviral drugs, especially NNRTIs, cross‐resistance is possible: any mutation that confers resistance to one drug will lead to resistance with all other drugs in the class (<a href="./references#CD006495-bbs2-0073" title="Sluis‐CremerN . The emerging profile of cross‐resistance among the nonnucleoside HIV‐1 reverse transcriptase inhibitors. Viruses2014;6(8):2960‐73. [PUBMED: 25089538] ">Sluis‐Cremer 2014</a>). This is a matter of particular concern, given the widespread use of NNRTIs in low‐resource settings (<a href="./references#CD006495-bbs2-0073" title="Sluis‐CremerN . The emerging profile of cross‐resistance among the nonnucleoside HIV‐1 reverse transcriptase inhibitors. Viruses2014;6(8):2960‐73. [PUBMED: 25089538] ">Sluis‐Cremer 2014</a>). The WHO currently recommends initiating ART with two NRTIs in addition to one NNRTI, or one INSTI. In the event of treatment failure, the NNRTI should be switched to a PI (<a href="./references#CD006495-bbs2-0083" title="World Health Organization. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection. Recommendations for a Public Health Approach. Second Edition. June 2016. www.who.int/hiv/pub/arv/arv‐2016/en/ (accessed 3 June 2017). ">WHO 2016</a>). </p> <p>Many problems exist in HIV care, including limited access to ART in some parts of the world, suboptimal levels of adherence, drug resistance, and treatment failure (<a href="./references#CD006495-bbs2-0079" title="UNAIDS . The Gap Report. 2014. http://files.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2014/UNAIDS_Gap_report_en.pdf (accessed 3 June 2017). ">UNAIDS 2014</a>; <a href="./references#CD006495-bbs2-0080" title="UNAIDS . Get on the Fast‐Track. The Life‐Cycle Approach to HIV. Finding Solutions for Everyone at Every Stage of Life. 2016. www.unaids.org/sites/default/files/media_asset/Get‐on‐the‐Fast‐Track_en.pdf (accessed 3 June 2017). ">UNAIDS 2016</a>). International commitment to a unified response to the HIV pandemic is improving access to ART, and numerous research efforts have attempted to pinpoint the best adherence enhancement strategies (<a href="./references#CD006495-bbs2-0040" title="ChaiyachatiKH , OgbuojiO , PriceM , SutharAB , NegussieEK , BärnighausenT . Interventions to improve adherence to antiretroviral therapy: a rapid systematic review. AIDS (London, England)2014;28(Suppl 2):S187‐204. [PUBMED: 24849479] ">Chaiyachati 2014</a>; <a href="./references#CD006495-bbs2-0057" title="KantersS , ParkJJ , ChanK , SociasME , FordN , ForrestJI , et al. Interventions to improve adherence to antiretroviral therapy: a systematic review and network meta‐analysis. Lancet HIV2017;4(1):e31‐40. [PUBMED: 27863996] ">Kanters 2017</a>; <a href="./references#CD006495-bbs2-0060" title="NachegaJB , UthmanOA , AndersonJ , PeltzerK , WampoldS , CottonMF , et al. Adherence to antiretroviral therapy during and after pregnancy in low‐income, middle‐income, and high‐income countries: a systematic review and meta‐analysis. AIDS (London, England)2012;26(16):2039‐52. [PUBMED: 22951634] ">Nachega 2012</a>; <a href="./references#CD006495-bbs2-0066" title="RamjanR , CalmyA , VitoriaM , MillsEJ , HillA , CookeG , et al. Systematic review and meta‐analysis: patient and programme impact of fixed‐dose combination antiretroviral therapy. Tropical Medicine &amp; International Health2014;19(5):501‐13. [PUBMED: 24628918] ">Ramjan 2014</a>; <a href="./references#CD006495-bbs2-0075" title="ThompsonMA , MugaveroMJ , AmicoKR , CargillVA , ChangLW , GrossR , et al. Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence‐based recommendations from an International Association of Physicians in AIDS Care Panel. Annals of Internal Medicine2012;156(11):817‐33, W‐284‐94. [PUBMED: 22393036] ">Thompson 2012</a>). However, viral resistance to ART can have an important impact on the lives of those affected. </p> <p>For HIV‐positive people who are taking ART, emergence of drug resistance poses a serious threat to a sustained virological response to treatment; it reduces effective therapeutic options and may increase morbidity, mortality, and infectivity (<a href="./references#CD006495-bbs2-0039" title="CambianoV , BertagnolioS , JordanMR , LundgrenJD , PhillipsA . Transmission of drug resistant HIV and its potential impact on mortality and treatment outcomes in resource‐limited settings. Journal of Infectious Diseases2013;207(Suppl 2):S57‐62. [PUBMED: 23687290] ">Cambiano 2013</a>; <a href="./references#CD006495-bbs2-0051" title="GuptaRK , JordanMR , SultanBJ , HillA , DavisDH , GregsonJ , et al. Global trends in antiretroviral resistance in treatment‐naive individuals with HIV after rollout of antiretroviral treatment in resource‐limited settings: a global collaborative study and meta‐regression analysis. Lancet (London, England)2012;380(9849):1250‐8. [PUBMED: 22828485] ">Gupta 2012</a>). All of the above have led to an increased healthcare burden for individuals and for society. Drug resistance may be transmitted (transmitted drug resistance: TDR) or acquired (drug resistance mutation: DRM; <a href="./references#CD006495-bbs2-0069" title="Rojas SánchezP , HolguínA . Drug resistance in the HIV‐1‐infected paediatric population worldwide: a systematic review. Journal of Antimicrobial Chemotherapy2014;69(8):2032‐42. [PUBMED: 24788658] ">Rojas Sánchez 2014</a>). People infected with highly resistant strains more often need to take ART (in spite of its higher costs, toxicity, and inconvenience) than those infected with HIV that is not antiretroviral‐resistant. </p> <p>Close to 68% of treatment‐experienced patients who experience failed treatment have resistance to at least one drug (<a href="./references#CD006495-bbs2-0087" title="World Health Organization. WHO HIV Drug Resistance Report 2017. http://apps.who.int/iris/bitstream/handle/10665/255896/9789241512831‐eng.pdf?sequence=1 (accessed 24 July 2018). ">WHO 2017c</a>). Even though recent data suggest that these numbers are dropping (<a href="./references#CD006495-bbs2-0042" title="DeLucaA , ZazziM . Interplay between transmitted and acquired HIV Type 1 drug resistance: reasons for a disconnect. Journal of Infectious Diseases2015;212(1):5‐7. ">De Luca 2015</a>), treatment‐experienced patients who are failing treatment may still benefit from earlier detection of resistance and an informed selection of a new regimen. </p> <p>The incidence of primary antiretroviral resistance is increasing (<a href="./references#CD006495-bbs2-0032" title="BakhouchK , Oulad‐LahcenA , BensghirR , BlaghenM , ElfilaliKM , EzzikouriS , et al. The prevalence of resistance‐associated mutations to protease and reverse transcriptase inhibitors in treatment‐naïve (HIV1)‐infected individuals in Casablanca, Morocco. Journal of Infection in Developing Countries2009;3(5):380‐91. ">Bakhouch 2009</a>; <a href="./references#CD006495-bbs2-0034" title="BarrowGJ , Hylton‐KongT , RodriguezN , YamamuraY , FigueroaJP . HIV‐1 drug resistance in treatment‐naive chronically infected patients in Jamaica. Antiviral Therapy2013;18(7):941‐4. [PUBMED: 23744572] ">Barrow 2013</a>; <a href="./references#CD006495-bbs2-0046" title="DuweS , BrunnM , AltmannD , HamoudaO , SchmidtB , WalterH , et al. Frequency of genotypic and phenotypic drug resistant HIV‐1 among therapy‐naive patients of the German Seroconverter Study. Journal of Acquired Immune Deficiency Syndromes2001;26(3):266‐73. [PUBMED: 11242200] ">Duwe 2001</a>; <a href="./references#CD006495-bbs2-0069" title="Rojas SánchezP , HolguínA . Drug resistance in the HIV‐1‐infected paediatric population worldwide: a systematic review. Journal of Antimicrobial Chemotherapy2014;69(8):2032‐42. [PUBMED: 24788658] ">Rojas Sánchez 2014</a>; <a href="./references#CD006495-bbs2-0077" title="TortiC , BonoL , GargiuloF , UccelliMC , Quiros‐RoldanE , PatroniA , et al. Prevalence of drug resistance and newly recognised treatment‐related substitutions in the HIV‐1 reverse transcriptase and protease genes from HIV‐positive patients naive for antiretrovirals. Clinical Microbiology and Infection2004;10(9):826‐30. [PUBMED: 15355414] ">Torti 2004</a>). This drug resistance would most likely involve TDR in newly infected individuals. The prevalence of TDR may be stable in high‐income countries (10% to 17% have resistance to at least one drug; <a href="./references#CD006495-bbs2-0087" title="World Health Organization. WHO HIV Drug Resistance Report 2017. http://apps.who.int/iris/bitstream/handle/10665/255896/9789241512831‐eng.pdf?sequence=1 (accessed 24 July 2018). ">WHO 2017c</a>), and it is on the rise in low‐income countries (<a href="./references#CD006495-bbs2-0063" title="PhamQD , WilsonDP , LawMG , KelleherAD , ZhangL . Global burden of transmitted HIV drug resistance and HIV‐exposure categories: a systematic review and meta‐analysis. AIDS2014;28(18):2751‐62. [DOI: 10.1097/QAD.0000000000000494] ">Pham 2014</a>). As the number of people on ART is increasing, the frequency of DRMs is also increasing (<a href="./references#CD006495-bbs2-0037" title="BoenderTS , KityoCM , BoermaRS , HamersRL , OndoaP , WellingtonM , et al. Accumulation of HIV‐1 drug resistance after continued virological failure on first‐line ART in adults and children in sub‐Saharan Africa. Journal of Antimicrobial Chemotherapy2016;71(10):2918‐27. [PUBMED: 27342546] ">Boender 2016</a>; <a href="./references#CD006495-bbs2-0070" title="RowleyCF , MacLeodIJ , MaruapulaD , LekokoB , GaseitsiweS , MineM , et al. Sharp increase in rates of HIV transmitted drug resistance at antenatal clinics in Botswana demonstrates the need for routine surveillance. Journal of Antimicrobial Chemotherapy2016;71(5):1361‐6. [PUBMED: 26929269] ">Rowley 2016</a>; <a href="./references#CD006495-bbs2-0081" title="Villabona‐ArenasCJ , VidalN , GuichetE , SerranoL , DelaporteE , GascuelO , et al. In‐depth analysis of HIV‐1 drug resistance mutations in HIV‐infected individuals failing first‐line regimens in West and Central Africa. AIDS (London, England)2016;30(17):2577‐89. [PUBMED: 27603287] ">Villabona‐Arenas 2016</a>). People with pretreatment drug resistance are more likely to experience treatment failure (<a href="./references#CD006495-bbs2-0053" title="HamersRL , SchuurmanR , SigaloffKC , WallisCL , KityoC , SiwaleM , et al. Effect of pretreatment HIV‐1 drug resistance on immunological, virological, and drug‐resistance outcomes of first‐line antiretroviral treatment in sub‐Saharan Africa: a multicentre cohort study. Lancet Infectious Diseases2012;12(4):307‐17. [PUBMED: 22036233] ">Hamers 2012</a>; <a href="./references#CD006495-bbs2-0088" title="WittkopL , GünthardHF , deWolfF , DunnD , Cozzi‐LepriA , deLucaA , et al. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord‐CHAIN joint project): a European multicohort study. Lancet Infectious Diseases2011;11(5):363‐71. ">Wittkop 2011</a>), have higher mortality rates (<a href="./references#CD006495-bbs2-0039" title="CambianoV , BertagnolioS , JordanMR , LundgrenJD , PhillipsA . Transmission of drug resistant HIV and its potential impact on mortality and treatment outcomes in resource‐limited settings. Journal of Infectious Diseases2013;207(Suppl 2):S57‐62. [PUBMED: 23687290] ">Cambiano 2013</a>; <a href="./references#CD006495-bbs2-0065" title="PinogesL , SchrammB , PouletE , BalkanS , SzumilinE , FerreyraC , et al. Risk factors and mortality associated with resistance to first‐line antiretroviral therapy: multicentric cross‐sectional and longitudinal analyses. Journal of Acquired Immune Deficiency Syndromes2015;68(5):527‐35. [PUBMED: 25585301] ">Pinoges 2015</a>), and need more frequent treatment switches during their course of care (<a href="./references#CD006495-bbs2-0036" title="BoenderTS , HoenderboomBM , SigaloffKC , HamersRL , WellingtonM , ShamuT , et al. Pretreatment HIV drug resistance increases regimen switches in sub‐Saharan Africa. Clinical Infectious Diseases2015;61(11):1749‐58. [PUBMED: 26240203] ">Boender 2015</a>). Irrespective of how drug resistance occurs, it represents a serious threat to the potency of ART in both ART‐naive and ART‐experienced patients. </p> </section> <section id="CD006495-sec-0033"> <h3 class="title" id="CD006495-sec-0033">Description of the intervention</h3> <p>Antiretroviral resistance testing is conducted in one of two ways: genotypic testing sequences the viral RNA and compares it against a database of known DRMs to determine which medications it is resistant to; phenotypic testing measures susceptibility of the virus to antiretroviral medications in a controlled environment exposed to specific antiretrovirals. Genotypic testing is less expensive and is more widely available. These tests provide information on resistance to the four main classes of ART (NRTIs, NNRTIs, PIs, and INSTIs; <a href="./references#CD006495-bbs2-0031" title="AIDSinfo . Guidelines for the Use of Antiretroviral Agents in HIV‐1‐Infected Adults and Adolescents. Laboratory Testing. Last Updated: 14 July 2016. http://aidsinfo.nih.gov/guidelines/html/1/adult‐and‐adolescent‐arv‐guidelines/6/drug‐resistance‐testing (accessed 03 June 2017). ">AIDSinfo 2016</a>). Genotypic testing can be completed within one to two weeks, but interpretation of results may be challenging without knowledge of specific gene mutations and the potential for cross‐resistance. Interpretation of genotypic testing is often aided by simultaneous reporting of predicted antiretroviral susceptibilities. Expert advice is often helpful in choosing the optimal ART after genotypic testing (<a href="./references#CD006495-bbs2-0010" title="TuralC , RuizL , HoltzerC , SchapiroJ , VicianaP , GonzalezJ , et al. Clinical utility of HIV‐1 genotyping and expert advice: the Havana trial. AIDS (London, England)2002;16(2):209‐18. [PUBMED: 11807305] ">Tural 2002</a>). Phenotypic tests take longer (two to three weeks), and they involve determining the ability of the virus to grow in various concentrations of antiretroviral drugs. Viral replication in the presence of antiretroviral drugs is then compared with replication of a reference HIV strain. Expert assistance may be helpful in guiding interpretation. Genotypic testing is the recommended approach for treatment‐naive and treatment‐experienced patients because it costs less, results can be available faster, and it is more sensitive in detecting mixtures of resistant and wild‐type viruses. Phenotypic testing can be added when complex mutation patterns are known or suspected (<a href="./references#CD006495-bbs2-0031" title="AIDSinfo . Guidelines for the Use of Antiretroviral Agents in HIV‐1‐Infected Adults and Adolescents. Laboratory Testing. Last Updated: 14 July 2016. http://aidsinfo.nih.gov/guidelines/html/1/adult‐and‐adolescent‐arv‐guidelines/6/drug‐resistance‐testing (accessed 03 June 2017). ">AIDSinfo 2016</a>). Overall, both tests are costly, are unlikely to detect resistant viruses that constitute less than 10% to 20% of the circulating virus population, and do not have uniform standards for quality assurance (<a href="./references#CD006495-bbs2-0031" title="AIDSinfo . Guidelines for the Use of Antiretroviral Agents in HIV‐1‐Infected Adults and Adolescents. Laboratory Testing. Last Updated: 14 July 2016. http://aidsinfo.nih.gov/guidelines/html/1/adult‐and‐adolescent‐arv‐guidelines/6/drug‐resistance‐testing (accessed 03 June 2017). ">AIDSinfo 2016</a>). </p> <p>Additional considerations for the use of resistance testing include timing of the test and viral load. The best results are obtained before or within four weeks of treatment discontinuation, but testing is challenging to perform in patients with low HIV viral loads (<a href="./references#CD006495-bbs2-0031" title="AIDSinfo . Guidelines for the Use of Antiretroviral Agents in HIV‐1‐Infected Adults and Adolescents. Laboratory Testing. Last Updated: 14 July 2016. http://aidsinfo.nih.gov/guidelines/html/1/adult‐and‐adolescent‐arv‐guidelines/6/drug‐resistance‐testing (accessed 03 June 2017). ">AIDSinfo 2016</a>). </p> </section> <section id="CD006495-sec-0034"> <h3 class="title" id="CD006495-sec-0034">How the intervention might work</h3> <p>Currently, the WHO recommends use of population‐based surveys to measure levels of drug resistance. Resistance testing should be considered before ART is initiated when the prevalence of NNRTI TDR is ≥ 10%, and when it is not feasible to provide non‐NNRTI‐based first‐line regimens for all starters owing to costs or availability (<a href="./references#CD006495-bbs2-0085" title="World Health Organization. Guidelines on the Public Health Response to Pretreatment HIV Drug Resistance. http://apps.who.int/iris/bitstream/handle/10665/255880/9789241550055‐eng.pdf?sequence=1 (accessed 25 July 2018). ">WHO 2017a</a>). Data from such population‐based surveys in resource‐limited settings suggest that at 12 months, approximately two‐thirds of those who do not achieve viral suppression on first‐line therapy have drug resistance (<a href="./references#CD006495-bbs2-0055" title="HosseinipourMC , GuptaRK , VanZylG , EronJJ , NachegaJB . Emergence of HIV drug resistance during first‐ and second‐line antiretroviral therapy in resource‐limited settings. Journal of Infectious Diseases2013;207(Suppl 2):S49‐56. [PUBMED: 23687289] ">Hosseinipour 2013</a>). The prevalence of TDR varies by exposure risk and is probably higher among men who have sex with men (MSM) and people who inject drugs (PWIDs; <a href="./references#CD006495-bbs2-0038" title="BurchellAN , BayoumiAM , RourkeSB , MajorC , GardnerS , SandstromP , et al. Increase in transmitted HIV drug resistance among persons undergoing genotypic resistance testing in Ontario, Canada, 2002‐09. Journal of Antimicrobial Chemotherapy2012;67:2755‐65. ">Burchell 2012</a>; <a href="./references#CD006495-bbs2-0068" title="RocheleauG , Franco‐VillalobosC , OliveiraN , BrummeZL , RuschM , ShovellerJ , et al. Sociodemographic correlates of HIV drug resistance and access to drug resistance testing in British Columbia, Canada. PLoS One2017;12:e0184848. ">Rocheleau 2017</a>; <a href="./references#CD006495-bbs2-0074" title="SullivanA , SutcliffeP , SandreR , HarriganR , ArchibaldC , HalversonJ , et al. Follow‐up investigation of a cluster of treatment‐naive HIV‐infected patients with multi‐drug resistance in Sudbury, Ontario. Canadian Journal of Infectious Diseases and Medical Microbiology2013;24:38A. ">Sullivan 2013</a>). Therefore population‐based thresholds are not optimal for guiding first‐line ART regimens for many subpopulations. Because viral resistance can compromise virological response and no reliable ways are known to accurately predict primary drug resistance in an individual in the absence of resistance testing, HIV outcomes may be improved if such testing is done before ART is initiated (<a href="./references#CD006495-bbs2-0033" title="BarennesH , GuilletS , LimsrengS , HimS , NouhinJ , HakC , et al. Virological failure and HIV‐1 drug resistance mutations among naive and antiretroviral pre‐treated patients entering the ESTHER program of Calmette Hospital in Cambodia. PLoS ONE2014;9(8):e105736. [DOI: 10.1371/journal.pone.0105736] ">Barennes 2014</a>). Mathematical models indicate that TDR might have a substantial impact on HIV mortality if not detected (<a href="./references#CD006495-bbs2-0039" title="CambianoV , BertagnolioS , JordanMR , LundgrenJD , PhillipsA . Transmission of drug resistant HIV and its potential impact on mortality and treatment outcomes in resource‐limited settings. Journal of Infectious Diseases2013;207(Suppl 2):S57‐62. [PUBMED: 23687290] ">Cambiano 2013</a>). </p> </section> <section id="CD006495-sec-0035"> <h3 class="title" id="CD006495-sec-0035">Why it is important to do this review</h3> <p>Both European HIV Drug Resistance Guidelines and International Antiviral Society‐USA guidelines recommend resistance testing before initiation of ART (<a href="./references#CD006495-bbs2-0047" title="European AIDS Clinical Society. Guidelines 2017. www.eacsociety.org/files/guidelines_9.0‐english.pdf (accessed 2 August 2018). ">EACS 2017</a>; <a href="./references#CD006495-bbs2-0071" title="SaagMS , BensonCA , GandhiRT , HoyJF , LandovitzRJ , MugaveroMJ , et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society‐USA Panel. JAMA2018;320(4):379‐96. [PUBMED: 30043070] ">Saag 2018</a>). The WHO does not recommend this approach for resource‐limited settings in which available treatment options are limited, costs of resistance testing are prohibitive, and prevalence of ART resistance may be low. The WHO recommends a survey‐based method to detect population‐level prevalence of resistance and to support adherence and drug supply continuity (<a href="./references#CD006495-bbs2-0085" title="World Health Organization. Guidelines on the Public Health Response to Pretreatment HIV Drug Resistance. http://apps.who.int/iris/bitstream/handle/10665/255880/9789241550055‐eng.pdf?sequence=1 (accessed 25 July 2018). ">WHO 2017a</a>). However, in settings that provide empirical first‐line therapy for most people, the most appropriate thresholds of population‐level resistance chosen for discontinuation of a first‐line ART regimen are unclear. In addition, certain subpopulations (such as pregnant women, MSM, PWIDs, and commercial sex workers (CSWs)) may have higher levels of TDR than are seen in the general population (<a href="./references#CD006495-bbs2-0035" title="BissioE , BarbasMG , BouzasMB , CudoláA , SalomónH , EspínolaL , et al. Pretreatment HIV‐1 drug resistance in Argentina: results from a surveillance study performed according to WHO‐proposed new methodology in 2014‐15. Journal of Antimicrobial Chemotherapy2017;72(2):504‐10. [PUBMED: 27789684] ">Bissio 2017</a>; <a href="./references#CD006495-bbs2-0038" title="BurchellAN , BayoumiAM , RourkeSB , MajorC , GardnerS , SandstromP , et al. Increase in transmitted HIV drug resistance among persons undergoing genotypic resistance testing in Ontario, Canada, 2002‐09. Journal of Antimicrobial Chemotherapy2012;67:2755‐65. ">Burchell 2012</a>; <a href="./references#CD006495-bbs2-0068" title="RocheleauG , Franco‐VillalobosC , OliveiraN , BrummeZL , RuschM , ShovellerJ , et al. Sociodemographic correlates of HIV drug resistance and access to drug resistance testing in British Columbia, Canada. PLoS One2017;12:e0184848. ">Rocheleau 2017</a>; <a href="./references#CD006495-bbs2-0074" title="SullivanA , SutcliffeP , SandreR , HarriganR , ArchibaldC , HalversonJ , et al. Follow‐up investigation of a cluster of treatment‐naive HIV‐infected patients with multi‐drug resistance in Sudbury, Ontario. Canadian Journal of Infectious Diseases and Medical Microbiology2013;24:38A. ">Sullivan 2013</a>). </p> <p>The US Centers for Disease Control and Prevention (CDC) recommends routine testing of all patients initiating ART based on observational data (<a href="./references#CD006495-bbs2-0031" title="AIDSinfo . Guidelines for the Use of Antiretroviral Agents in HIV‐1‐Infected Adults and Adolescents. Laboratory Testing. Last Updated: 14 July 2016. http://aidsinfo.nih.gov/guidelines/html/1/adult‐and‐adolescent‐arv‐guidelines/6/drug‐resistance‐testing (accessed 03 June 2017). ">AIDSinfo 2016</a>). One economic evaluation, based on a hypothetical cohort, reported that resistance testing is cost‐effective for treatment‐naive individuals (<a href="./references#CD006495-bbs2-0072" title="SaxPE , IslamR , WalenskyRP , LosinaE , WeinsteinMC , GoldieSJ , et al. Should resistance testing be performed for treatment‐naive HIV‐infected patients? A cost‐effectiveness analysis. Clinical Infectious Diseases2005;41(9):1316‐23. [PUBMED: 16206108] ">Sax 2005</a>). Cost‐effectiveness results are conflicting for treatment‐experienced patients, depending on which type of resistance testing is used (<a href="./references#CD006495-bbs2-0041" title="CorzilliusM , MühlbergerN , SroczynskiG , JaegerH , WasemJ , SiebertU . Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV. Antiviral Therapy2004;9(1):27‐36. [PUBMED: 15040534] ">Corzillius 2004</a>; <a href="./references#CD006495-bbs2-0064" title="PhillipsA , CambianoV , NakagawaF , MabuguT , MinersA , FordD , et al. Cost‐effectiveness of HIV drug resistance testing to inform switching to second line antiretroviral therapy in low income settings. PLoS ONE2014;9(10):e109148. [PUBMED: 25290340] ">Phillips 2014</a>). Previous systematic reviews prepared more than 10 years ago have focused solely on patients experiencing treatment failure and on short‐term outcomes (12 months) in high‐income countries (<a href="./references#CD006495-bbs2-0045" title="DunnDT , GibbDM , BabikerAG , GreenH , DarbyshireJH , WellerIV . HIV drug resistance testing: is the evidence really there?. Antiviral Therapy2004;9(5):641‐8. [PUBMED: 15535402] ">Dunn 2004</a>; <a href="./references#CD006495-bbs2-0049" title="EnaJ , Ruiz de ApodacaRF , AmadorC , BenitoC , PasquauF . Net benefits of resistance testing directed therapy compared with standard of care in HIV‐infected patients with virological failure: a meta‐analysis. Enfermedades Infecciosas y Microbiologia Clinica2006;24(4):232‐7. [PUBMED: 16725082] ">Ena 2006</a>; <a href="./references#CD006495-bbs2-0076" title="TorreD , TambiniR . Antiretroviral drug resistance testing in patients with HIV‐1 infection: a meta‐analysis study. HIV Clinical Trials2002;3(1):1‐8. [PUBMED: 11819179] ">Torre 2002</a>). <a href="./references#CD006495-bbs2-0076" title="TorreD , TambiniR . Antiretroviral drug resistance testing in patients with HIV‐1 infection: a meta‐analysis study. HIV Clinical Trials2002;3(1):1‐8. [PUBMED: 11819179] ">Torre 2002</a> found that viral suppression was more likely at three and six months after genotypic resistance testing but not after phenotypic testing. Viral suppression was also more likely when expert advice was provided. <a href="./references#CD006495-bbs2-0045" title="DunnDT , GibbDM , BabikerAG , GreenH , DarbyshireJH , WellerIV . HIV drug resistance testing: is the evidence really there?. Antiviral Therapy2004;9(5):641‐8. [PUBMED: 15535402] ">Dunn 2004</a> reported that a higher proportion of participants achieved viral suppression at three to six months among those who underwent resistance testing. <a href="./references#CD006495-bbs2-0049" title="EnaJ , Ruiz de ApodacaRF , AmadorC , BenitoC , PasquauF . Net benefits of resistance testing directed therapy compared with standard of care in HIV‐infected patients with virological failure: a meta‐analysis. Enfermedades Infecciosas y Microbiologia Clinica2006;24(4):232‐7. [PUBMED: 16725082] ">Ena 2006</a> reported similar results at three months and additional benefits if genotypic resistance testing was coupled with expert interpretation. However, given that more options are now available for second‐ and third‐line treatment in resource‐limited settings (<a href="./references#CD006495-bbs2-0083" title="World Health Organization. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection. Recommendations for a Public Health Approach. Second Edition. June 2016. www.who.int/hiv/pub/arv/arv‐2016/en/ (accessed 3 June 2017). ">WHO 2016</a>), the question of how to choose a new regimen after failure of the first‐line regimen in such settings is important, and more recent and applicable evidence is needed to answer this question. </p> <p>In this systematic review, we will use data from randomized trials and cohort studies to highlight the benefits or harms of conducting resistance testing in individuals before initiation of ART and after failure of first‐line treatment. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD006495-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD006495-sec-0036"></div> <p>To evaluate the effectiveness of antiretroviral resistance testing (genotypic or phenotypic) in reducing mortality and morbidity in HIV‐positive people. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD006495-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD006495-sec-0037"></div> <section id="CD006495-sec-0038"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD006495-sec-0039"> <h4 class="title">Types of studies</h4> <p>We searched for randomized controlled trials (RCTs) and cohort studies conducted to evaluate clinical and biological outcomes in treatment‐naive or treatment‐experienced people with HIV who undergo resistance testing compared to no resistance testing. </p> </section> <section id="CD006495-sec-0040"> <h4 class="title">Types of participants</h4> <p>We included people of any age who are HIV‐positive (with documented HIV infection as reported by study authors). </p> </section> <section id="CD006495-sec-0041"> <h4 class="title">Types of interventions</h4> <section id="CD006495-sec-0042"> <h5 class="title">Intervention</h5> <p>Interventions consisted of any type of resistance testing in people with HIV before initiation of therapy or after failure of first‐line therapy. We included genotypic and phenotypic tests. We included studies that compared different methods of resistance testing only if they included a control arm that underwent no testing. </p> </section> <section id="CD006495-sec-0043"> <h5 class="title">Control</h5> <p>Control groups were given no resistance testing.</p> </section> </section> <section id="CD006495-sec-0044"> <h4 class="title">Types of outcome measures</h4> <section id="CD006495-sec-0045"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD006495-list-0001"> <li> <p>Mortality (proportion of deaths)</p> </li> <li> <p>Virological success: the proportion of participants achieving undetectable viral load (using lower limits for detection and time frames defined by study authors) </p> </li> </ul> </p> </section> <section id="CD006495-sec-0046"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD006495-list-0002"> <li> <p>Change in mean CD4‐T‐lymphocyte count (immunological response) over time</p> </li> <li> <p>Clinical progression to AIDS: the proportion of participants who develop CDC‐defined AIDS (stages III and IV) </p> </li> <li> <p>Development of a second or new opportunistic infection</p> </li> <li> <p>Quality of life (as reported by study authors)</p> </li> <li> <p>Change in viral load</p> </li> </ul> </p> <section id="CD006495-sec-0047"> <h6 class="title">Adverse events</h6> <p> <ul id="CD006495-list-0003"> <li> <p>Any adverse events reported by study authors</p> </li> </ul> </p> </section> </section> </section> </section> <section id="CD006495-sec-0048"> <h3 class="title">Search methods for identification of studies</h3> <p>We performed our literature search with the assistance of an Information Specialist. We adopted a comprehensive and exhaustive search strategy to identify studies reported in all languages irrespective of publication status (published, unpublished, in press, or in progress). We conducted searches of literature from 1989 ‐ the year in which the first case of antiretroviral drug resistance was identified (<a href="./references#CD006495-bbs2-0058" title="LarderBA , RichmanDD . HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science1989;243(4899):1731‐4. [PUBMED: 2467383] ">Larder 1989</a>). </p> <p>In addition to key antiretroviral terms used in standard searches performed by the Cochrane Infectious Diseases Group, we included all appropriate terms relevant to antiretroviral resistance testing, including Medical Subject Heading (MeSH) terms. We also used Cochrane's Highly Sensitive Strategy for identifying reports of RCTs and additional terms for identifying observational studies. </p> <section id="CD006495-sec-0049"> <h4 class="title">Electronic searches</h4> <p>We searched the following electronic databases for relevant RCTs and observational studies. </p> <p> <ul id="CD006495-list-0004"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL), in the Cochrane Library (1 January 1989 to 26 January 2018) </p> </li> <li> <p>PubMed (1 January 1989 to 26 January 2018)</p> </li> <li> <p>Embase (1 January 1989 to 26 January 2018)</p> </li> <li> <p>Cumulative Index to Nursing and Allied Health Literature (CINAHL) (1 January 1989 to 26 January 2018) </p> </li> <li> <p>Latin American and Caribbean Health Sciences Literature (LILACS) (1 January 1989 to 26 January 2018) </p> </li> <li> <p>Web of Science (1 January 1989 to 26 January 2018)</p> </li> </ul> </p> <p>We have outlined our detailed search strategies in <a href="./appendices#CD006495-sec-0120">Appendix 1</a>, <a href="./appendices#CD006495-sec-0121">Appendix 2</a>, and <a href="./appendices#CD006495-sec-0122">Appendix 3</a>. </p> <section id="CD006495-sec-0050"> <h5 class="title">Conference abstracts</h5> <p>We searched conference abstract archives on the websites of the Conference on Retroviruses and Opportunistic Infections (CROI); the International AIDS Conference (IAC); and the International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention (IAS), for all available abstracts presented at all conferences from 1989 to 2017. </p> </section> <section id="CD006495-sec-0051"> <h5 class="title">Ongoing trials</h5> <p> <ul id="CD006495-list-0005"> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP)</p> </li> <li> <p>ClinicalTrials.gov</p> </li> </ul> </p> </section> </section> <section id="CD006495-sec-0052"> <h4 class="title">Searching other resources</h4> <p>We checked the reference lists of pertinent studies for other relevant studies. In addition, we contacted experts in the field. We invited experts who contributed to the WHO 2017 Guidelines Panel on Management of Drug Resistance to provide additional resources that would inform this review (<a href="./references#CD006495-bbs2-0085" title="World Health Organization. Guidelines on the Public Health Response to Pretreatment HIV Drug Resistance. http://apps.who.int/iris/bitstream/handle/10665/255880/9789241550055‐eng.pdf?sequence=1 (accessed 25 July 2018). ">WHO 2017a</a>). </p> </section> </section> <section id="CD006495-sec-0053"> <h3 class="title" id="CD006495-sec-0053">Data collection and analysis</h3> <p>We prepared a PRISMA diagram to present a summary of identification, screening, and inclusion of studies in this review (<a href="./references#CD006495-bbs2-0059" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , PRISMA Group. Preferred reporting items for systematic reviews and meta‐analyses: the PRISMA statement. International Journal of Surgery (London, England)2010;8(5):336‐41. [PUBMED: 20171303] ">Moher 2010</a>). </p> <section id="CD006495-sec-0054"> <h4 class="title">Selection of studies</h4> <p>Two review authors (TA, RS, or JT) independently inspected for relevance the titles and abstracts of all references identified by the search. We obtained full‐text copies of all potentially relevant articles and screened them using a pretested eligibility form. We included only studies that fulfilled our inclusion criteria. We resolved disagreements by consensus. When consensus could not be reached, we consulted a third review author (LM) for adjudication. We examined included manuscripts to ensure that they described unique patients whose data were not reported in another included study. If we had found overlapping studies, we would have included the larger, more comprehensive study. We reported the excluded studies and their reasons for exclusion in a <a href="./references#CD006495-sec-0132" title="">Characteristics of excluded studies</a> table. We illustrated the study selection process using a PRISMA diagram. </p> </section> <section id="CD006495-sec-0055"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (TA, RS, or JT) used pilot‐tested data extraction forms to independently extract and record data from the included studies. When disagreement arose between the two review authors, a third independent review author adjudicated (LM). When necessary (missing information or unclear reports), we contacted study authors for clarification. For reports not published in English, we invited other scientists with expertise in Cochrane methods to assist with screening and data extraction. We collected bibliometric information and data on participants, interventions, comparisons, outcomes, and study duration. </p> <section id="CD006495-sec-0056"> <h5 class="title">Bibliometric information</h5> <p> <ul id="CD006495-list-0006"> <li> <p>Full reference</p> </li> <li> <p>Country of study</p> </li> </ul> </p> </section> <section id="CD006495-sec-0057"> <h5 class="title">Participants</h5> <p> <ul id="CD006495-list-0007"> <li> <p>Inclusion criteria</p> </li> <li> <p>Exclusion criteria</p> </li> <li> <p>Age</p> </li> <li> <p>Comorbidities</p> </li> <li> <p>ART exposure (naive versus experienced)</p> </li> <li> <p>Numbers in intervention and control arms</p> </li> </ul> </p> </section> <section id="CD006495-sec-0058"> <h5 class="title">Interventions</h5> <p> <ul id="CD006495-list-0008"> <li> <p>Type of testing used</p> </li> <li> <p>Use of expert interpretation</p> </li> <li> <p>Drug regimens</p> </li> </ul> </p> </section> <section id="CD006495-sec-0059"> <h5 class="title">Comparisons</h5> <p> <ul id="CD006495-list-0009"> <li> <p>Details on nature of control group (no testing or delayed testing)</p> </li> </ul> </p> </section> <section id="CD006495-sec-0060"> <h5 class="title">Outcomes</h5> <p> <ul id="CD006495-list-0010"> <li> <p>Number of participants who experienced an event for dichotomous outcomes</p> </li> <li> <p>Means and standard deviations for normally distributed continuous outcomes (we standardized continuous data not reported on the same scale) </p> </li> </ul> </p> </section> <section id="CD006495-sec-0061"> <h5 class="title">Study duration</h5> <p> <ul id="CD006495-list-0011"> <li> <p>Duration of the study</p> </li> <li> <p>Timing of outcome measurement (in weeks or months)</p> </li> </ul> </p> </section> </section> <section id="CD006495-sec-0062"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed the risk of bias of randomized trials using the Cochrane ‘Risk of bias' assessment tool for the following items (<a href="./appendices#CD006495-sec-0123">Appendix 4</a>). </p> <p> <ul id="CD006495-list-0012"> <li> <p>Sequence generation: how the allocation sequence was generated and whether this was adequate </p> </li> <li> <p>Allocation concealment: how the allocation sequence was concealed and whether this was adequate </p> </li> <li> <p>Blinding of participants, personnel, and outcome assessors</p> </li> <li> <p>Description of the completeness of outcome data for each main outcome</p> </li> <li> <p>Selective outcome reporting</p> </li> <li> <p>Other potential sources of bias (e.g. funding)</p> </li> </ul> </p> <p>We graded included studies as having high, low, or unclear risk of bias, corresponding to assessments of yes, no, or unclear risk of bias. Two review authors independently performed ‘Risk of bias' assessments and prepared ‘Risk of bias' tables. </p> <p>Regarding the methodological quality of cohort studies, we planned to appraise this using the Newcastle‐Ottawa Scale (NOS; <a href="./references#CD006495-bbs2-0082" title="WellsGA , SheaB , O'ConnellD , PetersonJ , WelchV , LososM , et al. The Newcastle‐Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta‐analyses. 2009. www.ohri.ca/programs/clinical_epidemiology/oxford.asp (accessed 3 June 2017). ">Wells 2009</a>), which consists of assessments for the following items in three domains. </p> <p> <ul id="CD006495-list-0013"> <li> <p>Selection: representativeness of the exposed cohort, selection of the non‐exposed cohort, ascertainment of exposure, demonstration that the outcome of interest was not present at the start of the study </p> </li> <li> <p>Comparability: comparability of cohorts on the basis of design or analysis</p> </li> <li> <p>Outcomes: assessment of outcomes, duration of follow‐up, and adequacy of follow‐up</p> </li> </ul> </p> </section> <section id="CD006495-sec-0063"> <h4 class="title">Measures of treatment effect</h4> <p>We analysed the data using Review Manager 5 (RevMan 5) (<a href="./references#CD006495-bbs2-0067" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). We calculated the odds ratio (OR) for binary data, the weighted mean difference (WMD) for continuous data measured on the same scale, and the standard mean difference (SMD) for continuous data measured on different scales. We presented these results along with 95% confidence interval (CI) values. </p> </section> <section id="CD006495-sec-0064"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was the individual. We did not anticipate finding any cluster trials or cross‐over trials. </p> </section> <section id="CD006495-sec-0065"> <h4 class="title">Dealing with missing data</h4> <p>For missing or unclear data, we contacted the authors of included studies during the eligibility assessment and data extraction stages. We also sought missing data from secondary publications of the same study. In the event that we were unable to obtain the missing data, we conducted a complete‐case analysis. </p> </section> <section id="CD006495-sec-0066"> <h4 class="title">Assessment of heterogeneity</h4> <p>We first assessed included studies for clinical heterogeneity. If studies were similar enough that we could combine them (with regards to participants, interventions, comparisons, and outcomes), we performed a meta‐analysis and assessed statistical heterogeneity using the Chi² test for homogeneity with a level of significance of alpha = 0.10 and the I² statistic to quantify inconsistency. </p> </section> <section id="CD006495-sec-0067"> <h4 class="title">Assessment of reporting biases</h4> <p>We assessed reporting bias (selective outcome reporting) using the Cochrane ‘Risk of bias' assessment tool (<a href="./appendices#CD006495-sec-0123">Appendix 4</a>). We planned to assess publication bias using a funnel plot if 10 or more studies met the inclusion criteria (<a href="./references#CD006495-bbs2-0054" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. Version 5.0.2 [updated 2009]. The Cochrane Collaboration. ">Higgins 2011</a>). </p> </section> <section id="CD006495-sec-0068"> <h4 class="title">Data synthesis</h4> <p>We performed a random‐effects meta‐analysis to synthesize sufficiently similar quantitative data. We pooled the results of included studies to determine the odds ratio or the mean difference. We did not intend to pool data from randomized and non‐randomized studies. We planned to conduct analyses per exposure (i.e. data from treatment‐naive and treatment‐experienced people would be analysed separately). </p> <p>Reporting of change in HIV viral load and CD4 cell count varied across studies; therefore we performed calculations to obtain standard deviations from P values and pooled CIs from group means, as recommended in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD006495-bbs2-0054" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. Version 5.0.2 [updated 2009]. The Cochrane Collaboration. ">Higgins 2011</a>). We converted standard errors and CIs to standard deviations in RevMan 5 (<a href="./references#CD006495-bbs2-0067" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). We estimated means from medians when sample sizes were greater than 25, which has been shown to be a suitable estimate even in skewed distributions (<a href="./references#CD006495-bbs2-0056" title="HozoSP , DjulbegovicB , HozoI . Estimating the mean and variance from the median, range, and the size of a sample. BMC Medical Research Methodology2005;5:13. [PUBMED: 15840177] ">Hozo 2005</a>). We computed virological failure as the inverse of virological success to permit pooling across studies. </p> <section id="CD006495-sec-0069"> <h5 class="title">Certainty of the evidence</h5> <p>We assessed the certainty of the body of evidence using the GRADE approach (<a href="./references#CD006495-bbs2-0050" title="McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed 3 June 2017. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. ">GRADEpro 2015</a>), which defines the certainty of evidence for each outcome as the extent to which one can be confident that an estimate of effect or association is close to the quantity of specific interest. The certainty rating across studies has four levels: high, moderate, low, or very low. RCTs are categorized as high certainty evidence but can be downgraded; similarly, other types of controlled trials and observational studies are categorized as low certainty but can be upgraded. Factors that decrease the certainty of the evidence include limitations in design, indirectness of evidence, unexplained heterogeneity or inconsistency of results, imprecision of results, or high probability of publication bias. Factors that can increase the certainty level of a body of evidence include having a large magnitude of effect, whether plausible confounding would reduce a demonstrated effect, and if there is a dose‐response gradient (<a href="./references#CD006495-bbs2-0052" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction‐GRADE evidence profiles and summary of findings tables. Journal of clinical epidemiology2011;64(4):383‐94. [PUBMED: 21195583] ">Guyatt 2011</a>). We used the GRADEpro Guideline Development Tool (GDT) software to produce ‘Summary of findings' tables (<a href="./references#CD006495-bbs2-0050" title="McMaster University (developed by Evidence Prime). GRADEpro GDT. Version accessed 3 June 2017. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. ">GRADEpro 2015</a>). </p> </section> </section> <section id="CD006495-sec-0070"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to conduct subgroup analyses separately for studies that included treatment‐naive and treatment‐experienced people living with HIV. We prespecified the following subgroups. </p> <p> <ul id="CD006495-list-0014"> <li> <p>Potency of ART used (NNRTI‐ or PI‐based regimens)</p> </li> <li> <p>Type of resistance testing used (genotype or phenotype)</p> </li> <li> <p>Level of advancement of disease (Centers for Disease Control and Prevention (CDC) or WHO stage) </p> </li> <li> <p>Expert interpretation (use of expert advice to guide interpretation of resistance testing results) </p> </li> <li> <p>Age (children versus adults)</p> </li> </ul> </p> <p>We hypothesized that studies with more potent ART, more sophisticated resistance testing techniques, and patients at early stages of the disease whose choice of regimen is supported by expert advice would have relatively better outcomes with resistance testing compared to no resistance testing. Likewise, we expected that the benefits derived by ART‐naive patients would be better because these patients have a greater variety of potent drugs to choose from after completing resistance testing; patients in settings with a higher population‐level resistance rate would also experience greater benefit from resistance testing before therapy was initiated. We restricted subgroup analyses to those most relevant and those for which we had data. We interpreted subgroup results based on results of the between‐subgroups Chi² interaction test. </p> </section> <section id="CD006495-sec-0071"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to undertake a sensitivity analysis to evaluate bias introduced by variability in study design (observational versus randomized) and risk of bias. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD006495-sec-0072" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD006495-sec-0072"></div> <section id="CD006495-sec-0073"> <h3 class="title">Description of studies</h3> <section id="CD006495-sec-0074"> <h4 class="title">Results of the search</h4> <p>We conducted literature searches up to 26 January 2018, which yielded 3003 titles. Three review authors (TA, JT, and RS) independently screened the titles, abstracts, and descriptor terms of all material downloaded from the electronic searches to identify potentially relevant studies. After removing duplicates, we screened 2067 titles and abstracts, of which we excluded 2037 studies. We obtained the full‐text articles of 30 potentially relevant or uncertain reports. Eleven of them met our inclusion criteria. We excluded 19 after full‐text review. We have outlined our screening and selection process in <a href="#CD006495-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD006495-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="PRISMA study flow diagram." data-id="CD006495-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_n/nCD006495-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA study flow diagram.</p> </div> </div> </div> </section> <section id="CD006495-sec-0075"> <h4 class="title">Included studies</h4> <p>Eleven RCTs met the inclusion criteria of this Cochrane Review (<a href="./references#CD006495-bbs2-0001" title="BaxterJD , MayersDL , WentworthDN , NeatonJD , HooverML , WintersMA , et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS (London, England)2000;14(9):F83‐93. [PUBMED: 10894268] ">Baxter 2000</a>; <a href="./references#CD006495-bbs2-0002" title="CingolaniA , AntinoriA , RizzoMG , MurriR , AmmassariA , BaldiniF , et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS (London, England)2002;16(3):369‐79. [PUBMED: 11834948] ">Cingolani 2002</a>; <a href="./references#CD006495-bbs2-0003" title="CohenCJ , HuntS , SensionM , FarthingC , ConantM , JacobsonS , et al. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS (London, England)2002;16(4):579‐88. [PUBMED: 11873001] ">Cohen 2002</a>; <a href="./references#CD006495-bbs2-0004" title="Evaluation of Resistance Assays (ERA) Trial Investigators. A randomized controlled trial of the clinical utility of genotypic resistance testing in patients with limited prior exposure to antiretroviral drugs. HIV Clinical Trials2005;6(4):183‐6. [PUBMED: 16214734] ">Dunn 2005</a>; <a href="./references#CD006495-bbs2-0005" title="DurantJ , ClevenberghP , HalfonP , DelgiudiceP , PorsinS , SimonetP , et al. Drug‐resistance genotyping in HIV‐1 therapy: the VIRADAPT randomised controlled trial. Lancet (London, England)1999;353(9171):2195‐9. [PUBMED: 10392984] ">Durant 1999</a>; <a href="./references#CD006495-bbs2-0006" title="GreenH , GibbDM , CompagnucciA , GiacometV , deRossiA , HarperL , et al. A randomized controlled trial of genotypic HIV drug resistance testing in HIV‐1‐infected children: the PERA (PENTA 8) trial. Antiviral Therapy2006;11(7):857‐67. [PUBMED: 17302248] ">Green 2006</a>; <a href="./references#CD006495-bbs2-0007" title="HaubrichRH , KemperCA , HellmannNS , KeiserPH , WittMD , TillesJG , et al. A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575. AIDS (London, England)2005;19(3):295‐302. [PUBMED: 15718840] ">Haubrich 2005</a>; <a href="./references#CD006495-bbs2-0008" title="MeynardJL , VrayM , Morand‐JoubertL , RaceE , DescampsD , PeytavinG , et al. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS (London, England)2002;16(5):727‐36. [PUBMED: 11964529] ">Meynard 2002</a>; <a href="./references#CD006495-bbs2-0009" title="RubiniNPM , BrindeiroPA , BrindeiroRM , LlerenaCA , HertogsK , TanuriA . Clinical value of HIV‐1 genotyping in children and adolescents heavily experiences in antiretroviral therapy. XIV International AIDS Conference. Barcelona, 2002. ">Rubini 2002</a>; <a href="./references#CD006495-bbs2-0010" title="TuralC , RuizL , HoltzerC , SchapiroJ , VicianaP , GonzalezJ , et al. Clinical utility of HIV‐1 genotyping and expert advice: the Havana trial. AIDS (London, England)2002;16(2):209‐18. [PUBMED: 11807305] ">Tural 2002</a>; <a href="./references#CD006495-bbs2-0011" title="WegnerSA , WallaceMR , AronsonNE , TaskerSA , BlazesDL , TammingaC , et al. Long‐term efficacy of routine access to antiretroviral‐resistance testing in HIV type 1‐infected patients: results of the clinical efficacy of resistance testing trial. Clinical Infectious Diseases2004;38(5):723‐30. [PUBMED: 14986258] ">Wegner 2004</a>). The findings reported here are from papers or conference abstracts published between 1999 and 2005. Two study authors provided additional unpublished data (<a href="./references#CD006495-bbs2-0004" title="Evaluation of Resistance Assays (ERA) Trial Investigators. A randomized controlled trial of the clinical utility of genotypic resistance testing in patients with limited prior exposure to antiretroviral drugs. HIV Clinical Trials2005;6(4):183‐6. [PUBMED: 16214734] ">Dunn 2005</a>; <a href="./references#CD006495-bbs2-0010" title="TuralC , RuizL , HoltzerC , SchapiroJ , VicianaP , GonzalezJ , et al. Clinical utility of HIV‐1 genotyping and expert advice: the Havana trial. AIDS (London, England)2002;16(2):209‐18. [PUBMED: 11807305] ">Tural 2002</a>). See the <a href="./references#CD006495-sec-0131" title="">Characteristics of included studies</a> table. </p> <section id="CD006495-sec-0076"> <h5 class="title">Locations of studies</h5> <p>One trial was a multi‐national trial conducted in six countries: Italy, Brazil, UK, Spain, Germany, and Portugal (<a href="./references#CD006495-bbs2-0006" title="GreenH , GibbDM , CompagnucciA , GiacometV , deRossiA , HarperL , et al. A randomized controlled trial of genotypic HIV drug resistance testing in HIV‐1‐infected children: the PERA (PENTA 8) trial. Antiviral Therapy2006;11(7):857‐67. [PUBMED: 17302248] ">Green 2006</a>). Four trials were conducted in the USA (<a href="./references#CD006495-bbs2-0001" title="BaxterJD , MayersDL , WentworthDN , NeatonJD , HooverML , WintersMA , et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS (London, England)2000;14(9):F83‐93. [PUBMED: 10894268] ">Baxter 2000</a>; <a href="./references#CD006495-bbs2-0003" title="CohenCJ , HuntS , SensionM , FarthingC , ConantM , JacobsonS , et al. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS (London, England)2002;16(4):579‐88. [PUBMED: 11873001] ">Cohen 2002</a>; <a href="./references#CD006495-bbs2-0007" title="HaubrichRH , KemperCA , HellmannNS , KeiserPH , WittMD , TillesJG , et al. A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575. AIDS (London, England)2005;19(3):295‐302. [PUBMED: 15718840] ">Haubrich 2005</a>; <a href="./references#CD006495-bbs2-0011" title="WegnerSA , WallaceMR , AronsonNE , TaskerSA , BlazesDL , TammingaC , et al. Long‐term efficacy of routine access to antiretroviral‐resistance testing in HIV type 1‐infected patients: results of the clinical efficacy of resistance testing trial. Clinical Infectious Diseases2004;38(5):723‐30. [PUBMED: 14986258] ">Wegner 2004</a>); two in France (<a href="./references#CD006495-bbs2-0005" title="DurantJ , ClevenberghP , HalfonP , DelgiudiceP , PorsinS , SimonetP , et al. Drug‐resistance genotyping in HIV‐1 therapy: the VIRADAPT randomised controlled trial. Lancet (London, England)1999;353(9171):2195‐9. [PUBMED: 10392984] ">Durant 1999</a>; <a href="./references#CD006495-bbs2-0008" title="MeynardJL , VrayM , Morand‐JoubertL , RaceE , DescampsD , PeytavinG , et al. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS (London, England)2002;16(5):727‐36. [PUBMED: 11964529] ">Meynard 2002</a>); and one each in Italy (<a href="./references#CD006495-bbs2-0002" title="CingolaniA , AntinoriA , RizzoMG , MurriR , AmmassariA , BaldiniF , et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS (London, England)2002;16(3):369‐79. [PUBMED: 11834948] ">Cingolani 2002</a>), Spain (<a href="./references#CD006495-bbs2-0010" title="TuralC , RuizL , HoltzerC , SchapiroJ , VicianaP , GonzalezJ , et al. Clinical utility of HIV‐1 genotyping and expert advice: the Havana trial. AIDS (London, England)2002;16(2):209‐18. [PUBMED: 11807305] ">Tural 2002</a>), Brazil (<a href="./references#CD006495-bbs2-0009" title="RubiniNPM , BrindeiroPA , BrindeiroRM , LlerenaCA , HertogsK , TanuriA . Clinical value of HIV‐1 genotyping in children and adolescents heavily experiences in antiretroviral therapy. XIV International AIDS Conference. Barcelona, 2002. ">Rubini 2002</a>), and UK (<a href="./references#CD006495-bbs2-0004" title="Evaluation of Resistance Assays (ERA) Trial Investigators. A randomized controlled trial of the clinical utility of genotypic resistance testing in patients with limited prior exposure to antiretroviral drugs. HIV Clinical Trials2005;6(4):183‐6. [PUBMED: 16214734] ">Dunn 2005</a>). </p> </section> <section id="CD006495-sec-0077"> <h5 class="title">Study participants</h5> <p>All 11 trials exclusively included participants who were treatment‐experienced and whose therapy was failing (<a href="./references#CD006495-bbs2-0001" title="BaxterJD , MayersDL , WentworthDN , NeatonJD , HooverML , WintersMA , et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS (London, England)2000;14(9):F83‐93. [PUBMED: 10894268] ">Baxter 2000</a>; <a href="./references#CD006495-bbs2-0002" title="CingolaniA , AntinoriA , RizzoMG , MurriR , AmmassariA , BaldiniF , et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS (London, England)2002;16(3):369‐79. [PUBMED: 11834948] ">Cingolani 2002</a>; <a href="./references#CD006495-bbs2-0003" title="CohenCJ , HuntS , SensionM , FarthingC , ConantM , JacobsonS , et al. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS (London, England)2002;16(4):579‐88. [PUBMED: 11873001] ">Cohen 2002</a>; <a href="./references#CD006495-bbs2-0004" title="Evaluation of Resistance Assays (ERA) Trial Investigators. A randomized controlled trial of the clinical utility of genotypic resistance testing in patients with limited prior exposure to antiretroviral drugs. HIV Clinical Trials2005;6(4):183‐6. [PUBMED: 16214734] ">Dunn 2005</a>; <a href="./references#CD006495-bbs2-0005" title="DurantJ , ClevenberghP , HalfonP , DelgiudiceP , PorsinS , SimonetP , et al. Drug‐resistance genotyping in HIV‐1 therapy: the VIRADAPT randomised controlled trial. Lancet (London, England)1999;353(9171):2195‐9. [PUBMED: 10392984] ">Durant 1999</a>; <a href="./references#CD006495-bbs2-0006" title="GreenH , GibbDM , CompagnucciA , GiacometV , deRossiA , HarperL , et al. A randomized controlled trial of genotypic HIV drug resistance testing in HIV‐1‐infected children: the PERA (PENTA 8) trial. Antiviral Therapy2006;11(7):857‐67. [PUBMED: 17302248] ">Green 2006</a>; <a href="./references#CD006495-bbs2-0007" title="HaubrichRH , KemperCA , HellmannNS , KeiserPH , WittMD , TillesJG , et al. A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575. AIDS (London, England)2005;19(3):295‐302. [PUBMED: 15718840] ">Haubrich 2005</a>; <a href="./references#CD006495-bbs2-0008" title="MeynardJL , VrayM , Morand‐JoubertL , RaceE , DescampsD , PeytavinG , et al. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS (London, England)2002;16(5):727‐36. [PUBMED: 11964529] ">Meynard 2002</a>; <a href="./references#CD006495-bbs2-0009" title="RubiniNPM , BrindeiroPA , BrindeiroRM , LlerenaCA , HertogsK , TanuriA . Clinical value of HIV‐1 genotyping in children and adolescents heavily experiences in antiretroviral therapy. XIV International AIDS Conference. Barcelona, 2002. ">Rubini 2002</a>; <a href="./references#CD006495-bbs2-0010" title="TuralC , RuizL , HoltzerC , SchapiroJ , VicianaP , GonzalezJ , et al. Clinical utility of HIV‐1 genotyping and expert advice: the Havana trial. AIDS (London, England)2002;16(2):209‐18. [PUBMED: 11807305] ">Tural 2002</a>; <a href="./references#CD006495-bbs2-0011" title="WegnerSA , WallaceMR , AronsonNE , TaskerSA , BlazesDL , TammingaC , et al. Long‐term efficacy of routine access to antiretroviral‐resistance testing in HIV type 1‐infected patients: results of the clinical efficacy of resistance testing trial. Clinical Infectious Diseases2004;38(5):723‐30. [PUBMED: 14986258] ">Wegner 2004</a>). One study included children exclusively (three months to 18 years of age; <a href="./references#CD006495-bbs2-0006" title="GreenH , GibbDM , CompagnucciA , GiacometV , deRossiA , HarperL , et al. A randomized controlled trial of genotypic HIV drug resistance testing in HIV‐1‐infected children: the PERA (PENTA 8) trial. Antiviral Therapy2006;11(7):857‐67. [PUBMED: 17302248] ">Green 2006</a>). Two studies included both adolescents and adults (13 years of age or older; <a href="./references#CD006495-bbs2-0001" title="BaxterJD , MayersDL , WentworthDN , NeatonJD , HooverML , WintersMA , et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS (London, England)2000;14(9):F83‐93. [PUBMED: 10894268] ">Baxter 2000</a>; <a href="./references#CD006495-bbs2-0003" title="CohenCJ , HuntS , SensionM , FarthingC , ConantM , JacobsonS , et al. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS (London, England)2002;16(4):579‐88. [PUBMED: 11873001] ">Cohen 2002</a>). Another study included children and adolescents (<a href="./references#CD006495-bbs2-0009" title="RubiniNPM , BrindeiroPA , BrindeiroRM , LlerenaCA , HertogsK , TanuriA . Clinical value of HIV‐1 genotyping in children and adolescents heavily experiences in antiretroviral therapy. XIV International AIDS Conference. Barcelona, 2002. ">Rubini 2002</a>). One study did not report participant age (<a href="./references#CD006495-bbs2-0004" title="Evaluation of Resistance Assays (ERA) Trial Investigators. A randomized controlled trial of the clinical utility of genotypic resistance testing in patients with limited prior exposure to antiretroviral drugs. HIV Clinical Trials2005;6(4):183‐6. [PUBMED: 16214734] ">Dunn 2005</a>). Remaining studies included adults only (<a href="./references#CD006495-bbs2-0005" title="DurantJ , ClevenberghP , HalfonP , DelgiudiceP , PorsinS , SimonetP , et al. Drug‐resistance genotyping in HIV‐1 therapy: the VIRADAPT randomised controlled trial. Lancet (London, England)1999;353(9171):2195‐9. [PUBMED: 10392984] ">Durant 1999</a>; <a href="./references#CD006495-bbs2-0007" title="HaubrichRH , KemperCA , HellmannNS , KeiserPH , WittMD , TillesJG , et al. A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575. AIDS (London, England)2005;19(3):295‐302. [PUBMED: 15718840] ">Haubrich 2005</a>; <a href="./references#CD006495-bbs2-0008" title="MeynardJL , VrayM , Morand‐JoubertL , RaceE , DescampsD , PeytavinG , et al. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS (London, England)2002;16(5):727‐36. [PUBMED: 11964529] ">Meynard 2002</a>; <a href="./references#CD006495-bbs2-0010" title="TuralC , RuizL , HoltzerC , SchapiroJ , VicianaP , GonzalezJ , et al. Clinical utility of HIV‐1 genotyping and expert advice: the Havana trial. AIDS (London, England)2002;16(2):209‐18. [PUBMED: 11807305] ">Tural 2002</a>; <a href="./references#CD006495-bbs2-0011" title="WegnerSA , WallaceMR , AronsonNE , TaskerSA , BlazesDL , TammingaC , et al. Long‐term efficacy of routine access to antiretroviral‐resistance testing in HIV type 1‐infected patients: results of the clinical efficacy of resistance testing trial. Clinical Infectious Diseases2004;38(5):723‐30. [PUBMED: 14986258] ">Wegner 2004</a>). </p> </section> <section id="CD006495-sec-0078"> <h5 class="title">Interventions provided</h5> <p>Seven trials compared genotypic testing versus usual care (<a href="./references#CD006495-bbs2-0001" title="BaxterJD , MayersDL , WentworthDN , NeatonJD , HooverML , WintersMA , et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS (London, England)2000;14(9):F83‐93. [PUBMED: 10894268] ">Baxter 2000</a>; <a href="./references#CD006495-bbs2-0002" title="CingolaniA , AntinoriA , RizzoMG , MurriR , AmmassariA , BaldiniF , et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS (London, England)2002;16(3):369‐79. [PUBMED: 11834948] ">Cingolani 2002</a>; <a href="./references#CD006495-bbs2-0004" title="Evaluation of Resistance Assays (ERA) Trial Investigators. A randomized controlled trial of the clinical utility of genotypic resistance testing in patients with limited prior exposure to antiretroviral drugs. HIV Clinical Trials2005;6(4):183‐6. [PUBMED: 16214734] ">Dunn 2005</a>; <a href="./references#CD006495-bbs2-0005" title="DurantJ , ClevenberghP , HalfonP , DelgiudiceP , PorsinS , SimonetP , et al. Drug‐resistance genotyping in HIV‐1 therapy: the VIRADAPT randomised controlled trial. Lancet (London, England)1999;353(9171):2195‐9. [PUBMED: 10392984] ">Durant 1999</a>; <a href="./references#CD006495-bbs2-0006" title="GreenH , GibbDM , CompagnucciA , GiacometV , deRossiA , HarperL , et al. A randomized controlled trial of genotypic HIV drug resistance testing in HIV‐1‐infected children: the PERA (PENTA 8) trial. Antiviral Therapy2006;11(7):857‐67. [PUBMED: 17302248] ">Green 2006</a>; <a href="./references#CD006495-bbs2-0009" title="RubiniNPM , BrindeiroPA , BrindeiroRM , LlerenaCA , HertogsK , TanuriA . Clinical value of HIV‐1 genotyping in children and adolescents heavily experiences in antiretroviral therapy. XIV International AIDS Conference. Barcelona, 2002. ">Rubini 2002</a>; <a href="./references#CD006495-bbs2-0010" title="TuralC , RuizL , HoltzerC , SchapiroJ , VicianaP , GonzalezJ , et al. Clinical utility of HIV‐1 genotyping and expert advice: the Havana trial. AIDS (London, England)2002;16(2):209‐18. [PUBMED: 11807305] ">Tural 2002</a>). Two trials compared phenotypic testing versus usual care (<a href="./references#CD006495-bbs2-0003" title="CohenCJ , HuntS , SensionM , FarthingC , ConantM , JacobsonS , et al. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS (London, England)2002;16(4):579‐88. [PUBMED: 11873001] ">Cohen 2002</a>; <a href="./references#CD006495-bbs2-0007" title="HaubrichRH , KemperCA , HellmannNS , KeiserPH , WittMD , TillesJG , et al. A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575. AIDS (London, England)2005;19(3):295‐302. [PUBMED: 15718840] ">Haubrich 2005</a>). Two trials compared genotypic and phenotypic testing versus usual care (<a href="./references#CD006495-bbs2-0008" title="MeynardJL , VrayM , Morand‐JoubertL , RaceE , DescampsD , PeytavinG , et al. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS (London, England)2002;16(5):727‐36. [PUBMED: 11964529] ">Meynard 2002</a>; <a href="./references#CD006495-bbs2-0011" title="WegnerSA , WallaceMR , AronsonNE , TaskerSA , BlazesDL , TammingaC , et al. Long‐term efficacy of routine access to antiretroviral‐resistance testing in HIV type 1‐infected patients: results of the clinical efficacy of resistance testing trial. Clinical Infectious Diseases2004;38(5):723‐30. [PUBMED: 14986258] ">Wegner 2004</a>). Three trials included expert advice on interpretation of the resistance tests (<a href="./references#CD006495-bbs2-0001" title="BaxterJD , MayersDL , WentworthDN , NeatonJD , HooverML , WintersMA , et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS (London, England)2000;14(9):F83‐93. [PUBMED: 10894268] ">Baxter 2000</a>; <a href="./references#CD006495-bbs2-0002" title="CingolaniA , AntinoriA , RizzoMG , MurriR , AmmassariA , BaldiniF , et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS (London, England)2002;16(3):369‐79. [PUBMED: 11834948] ">Cingolani 2002</a>; <a href="./references#CD006495-bbs2-0010" title="TuralC , RuizL , HoltzerC , SchapiroJ , VicianaP , GonzalezJ , et al. Clinical utility of HIV‐1 genotyping and expert advice: the Havana trial. AIDS (London, England)2002;16(2):209‐18. [PUBMED: 11807305] ">Tural 2002</a>). </p> </section> <section id="CD006495-sec-0079"> <h5 class="title">Outcomes reported</h5> <p>Six trials reported mortality (<a href="./references#CD006495-bbs2-0001" title="BaxterJD , MayersDL , WentworthDN , NeatonJD , HooverML , WintersMA , et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS (London, England)2000;14(9):F83‐93. [PUBMED: 10894268] ">Baxter 2000</a>; <a href="./references#CD006495-bbs2-0005" title="DurantJ , ClevenberghP , HalfonP , DelgiudiceP , PorsinS , SimonetP , et al. Drug‐resistance genotyping in HIV‐1 therapy: the VIRADAPT randomised controlled trial. Lancet (London, England)1999;353(9171):2195‐9. [PUBMED: 10392984] ">Durant 1999</a>; <a href="./references#CD006495-bbs2-0006" title="GreenH , GibbDM , CompagnucciA , GiacometV , deRossiA , HarperL , et al. A randomized controlled trial of genotypic HIV drug resistance testing in HIV‐1‐infected children: the PERA (PENTA 8) trial. Antiviral Therapy2006;11(7):857‐67. [PUBMED: 17302248] ">Green 2006</a>; <a href="./references#CD006495-bbs2-0008" title="MeynardJL , VrayM , Morand‐JoubertL , RaceE , DescampsD , PeytavinG , et al. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS (London, England)2002;16(5):727‐36. [PUBMED: 11964529] ">Meynard 2002</a>; <a href="./references#CD006495-bbs2-0010" title="TuralC , RuizL , HoltzerC , SchapiroJ , VicianaP , GonzalezJ , et al. Clinical utility of HIV‐1 genotyping and expert advice: the Havana trial. AIDS (London, England)2002;16(2):209‐18. [PUBMED: 11807305] ">Tural 2002</a>; <a href="./references#CD006495-bbs2-0011" title="WegnerSA , WallaceMR , AronsonNE , TaskerSA , BlazesDL , TammingaC , et al. Long‐term efficacy of routine access to antiretroviral‐resistance testing in HIV type 1‐infected patients: results of the clinical efficacy of resistance testing trial. Clinical Infectious Diseases2004;38(5):723‐30. [PUBMED: 14986258] ">Wegner 2004</a>); 10 reported virological success (<a href="./references#CD006495-bbs2-0001" title="BaxterJD , MayersDL , WentworthDN , NeatonJD , HooverML , WintersMA , et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS (London, England)2000;14(9):F83‐93. [PUBMED: 10894268] ">Baxter 2000</a>; <a href="./references#CD006495-bbs2-0002" title="CingolaniA , AntinoriA , RizzoMG , MurriR , AmmassariA , BaldiniF , et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS (London, England)2002;16(3):369‐79. [PUBMED: 11834948] ">Cingolani 2002</a>; <a href="./references#CD006495-bbs2-0003" title="CohenCJ , HuntS , SensionM , FarthingC , ConantM , JacobsonS , et al. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS (London, England)2002;16(4):579‐88. [PUBMED: 11873001] ">Cohen 2002</a>; <a href="./references#CD006495-bbs2-0004" title="Evaluation of Resistance Assays (ERA) Trial Investigators. A randomized controlled trial of the clinical utility of genotypic resistance testing in patients with limited prior exposure to antiretroviral drugs. HIV Clinical Trials2005;6(4):183‐6. [PUBMED: 16214734] ">Dunn 2005</a>; <a href="./references#CD006495-bbs2-0005" title="DurantJ , ClevenberghP , HalfonP , DelgiudiceP , PorsinS , SimonetP , et al. Drug‐resistance genotyping in HIV‐1 therapy: the VIRADAPT randomised controlled trial. Lancet (London, England)1999;353(9171):2195‐9. [PUBMED: 10392984] ">Durant 1999</a>; <a href="./references#CD006495-bbs2-0006" title="GreenH , GibbDM , CompagnucciA , GiacometV , deRossiA , HarperL , et al. A randomized controlled trial of genotypic HIV drug resistance testing in HIV‐1‐infected children: the PERA (PENTA 8) trial. Antiviral Therapy2006;11(7):857‐67. [PUBMED: 17302248] ">Green 2006</a>; <a href="./references#CD006495-bbs2-0007" title="HaubrichRH , KemperCA , HellmannNS , KeiserPH , WittMD , TillesJG , et al. A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575. AIDS (London, England)2005;19(3):295‐302. [PUBMED: 15718840] ">Haubrich 2005</a>; <a href="./references#CD006495-bbs2-0008" title="MeynardJL , VrayM , Morand‐JoubertL , RaceE , DescampsD , PeytavinG , et al. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS (London, England)2002;16(5):727‐36. [PUBMED: 11964529] ">Meynard 2002</a>; <a href="./references#CD006495-bbs2-0009" title="RubiniNPM , BrindeiroPA , BrindeiroRM , LlerenaCA , HertogsK , TanuriA . Clinical value of HIV‐1 genotyping in children and adolescents heavily experiences in antiretroviral therapy. XIV International AIDS Conference. Barcelona, 2002. ">Rubini 2002</a>; <a href="./references#CD006495-bbs2-0010" title="TuralC , RuizL , HoltzerC , SchapiroJ , VicianaP , GonzalezJ , et al. Clinical utility of HIV‐1 genotyping and expert advice: the Havana trial. AIDS (London, England)2002;16(2):209‐18. [PUBMED: 11807305] ">Tural 2002</a>); eight reported change in mean CD4 count (<a href="./references#CD006495-bbs2-0001" title="BaxterJD , MayersDL , WentworthDN , NeatonJD , HooverML , WintersMA , et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS (London, England)2000;14(9):F83‐93. [PUBMED: 10894268] ">Baxter 2000</a>; <a href="./references#CD006495-bbs2-0002" title="CingolaniA , AntinoriA , RizzoMG , MurriR , AmmassariA , BaldiniF , et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS (London, England)2002;16(3):369‐79. [PUBMED: 11834948] ">Cingolani 2002</a>; <a href="./references#CD006495-bbs2-0003" title="CohenCJ , HuntS , SensionM , FarthingC , ConantM , JacobsonS , et al. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS (London, England)2002;16(4):579‐88. [PUBMED: 11873001] ">Cohen 2002</a>; <a href="./references#CD006495-bbs2-0004" title="Evaluation of Resistance Assays (ERA) Trial Investigators. A randomized controlled trial of the clinical utility of genotypic resistance testing in patients with limited prior exposure to antiretroviral drugs. HIV Clinical Trials2005;6(4):183‐6. [PUBMED: 16214734] ">Dunn 2005</a>; <a href="./references#CD006495-bbs2-0005" title="DurantJ , ClevenberghP , HalfonP , DelgiudiceP , PorsinS , SimonetP , et al. Drug‐resistance genotyping in HIV‐1 therapy: the VIRADAPT randomised controlled trial. Lancet (London, England)1999;353(9171):2195‐9. [PUBMED: 10392984] ">Durant 1999</a>; <a href="./references#CD006495-bbs2-0006" title="GreenH , GibbDM , CompagnucciA , GiacometV , deRossiA , HarperL , et al. A randomized controlled trial of genotypic HIV drug resistance testing in HIV‐1‐infected children: the PERA (PENTA 8) trial. Antiviral Therapy2006;11(7):857‐67. [PUBMED: 17302248] ">Green 2006</a>; <a href="./references#CD006495-bbs2-0007" title="HaubrichRH , KemperCA , HellmannNS , KeiserPH , WittMD , TillesJG , et al. A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575. AIDS (London, England)2005;19(3):295‐302. [PUBMED: 15718840] ">Haubrich 2005</a>; <a href="./references#CD006495-bbs2-0008" title="MeynardJL , VrayM , Morand‐JoubertL , RaceE , DescampsD , PeytavinG , et al. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS (London, England)2002;16(5):727‐36. [PUBMED: 11964529] ">Meynard 2002</a>); and three reported clinical progression to AIDS (<a href="./references#CD006495-bbs2-0005" title="DurantJ , ClevenberghP , HalfonP , DelgiudiceP , PorsinS , SimonetP , et al. Drug‐resistance genotyping in HIV‐1 therapy: the VIRADAPT randomised controlled trial. Lancet (London, England)1999;353(9171):2195‐9. [PUBMED: 10392984] ">Durant 1999</a>; <a href="./references#CD006495-bbs2-0006" title="GreenH , GibbDM , CompagnucciA , GiacometV , deRossiA , HarperL , et al. A randomized controlled trial of genotypic HIV drug resistance testing in HIV‐1‐infected children: the PERA (PENTA 8) trial. Antiviral Therapy2006;11(7):857‐67. [PUBMED: 17302248] ">Green 2006</a>; <a href="./references#CD006495-bbs2-0008" title="MeynardJL , VrayM , Morand‐JoubertL , RaceE , DescampsD , PeytavinG , et al. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS (London, England)2002;16(5):727‐36. [PUBMED: 11964529] ">Meynard 2002</a>). No trials reported on the development of a second or new opportunistic infection or on quality of life. Four trials reported any adverse events (<a href="./references#CD006495-bbs2-0001" title="BaxterJD , MayersDL , WentworthDN , NeatonJD , HooverML , WintersMA , et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS (London, England)2000;14(9):F83‐93. [PUBMED: 10894268] ">Baxter 2000</a>; <a href="./references#CD006495-bbs2-0003" title="CohenCJ , HuntS , SensionM , FarthingC , ConantM , JacobsonS , et al. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS (London, England)2002;16(4):579‐88. [PUBMED: 11873001] ">Cohen 2002</a>; <a href="./references#CD006495-bbs2-0005" title="DurantJ , ClevenberghP , HalfonP , DelgiudiceP , PorsinS , SimonetP , et al. Drug‐resistance genotyping in HIV‐1 therapy: the VIRADAPT randomised controlled trial. Lancet (London, England)1999;353(9171):2195‐9. [PUBMED: 10392984] ">Durant 1999</a>; <a href="./references#CD006495-bbs2-0010" title="TuralC , RuizL , HoltzerC , SchapiroJ , VicianaP , GonzalezJ , et al. Clinical utility of HIV‐1 genotyping and expert advice: the Havana trial. AIDS (London, England)2002;16(2):209‐18. [PUBMED: 11807305] ">Tural 2002</a>). Additional outcomes reported in 10 trials included change in viral load (<a href="./references#CD006495-bbs2-0001" title="BaxterJD , MayersDL , WentworthDN , NeatonJD , HooverML , WintersMA , et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS (London, England)2000;14(9):F83‐93. [PUBMED: 10894268] ">Baxter 2000</a>; <a href="./references#CD006495-bbs2-0002" title="CingolaniA , AntinoriA , RizzoMG , MurriR , AmmassariA , BaldiniF , et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS (London, England)2002;16(3):369‐79. [PUBMED: 11834948] ">Cingolani 2002</a>; <a href="./references#CD006495-bbs2-0003" title="CohenCJ , HuntS , SensionM , FarthingC , ConantM , JacobsonS , et al. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS (London, England)2002;16(4):579‐88. [PUBMED: 11873001] ">Cohen 2002</a>; <a href="./references#CD006495-bbs2-0004" title="Evaluation of Resistance Assays (ERA) Trial Investigators. A randomized controlled trial of the clinical utility of genotypic resistance testing in patients with limited prior exposure to antiretroviral drugs. HIV Clinical Trials2005;6(4):183‐6. [PUBMED: 16214734] ">Dunn 2005</a>; <a href="./references#CD006495-bbs2-0005" title="DurantJ , ClevenberghP , HalfonP , DelgiudiceP , PorsinS , SimonetP , et al. Drug‐resistance genotyping in HIV‐1 therapy: the VIRADAPT randomised controlled trial. Lancet (London, England)1999;353(9171):2195‐9. [PUBMED: 10392984] ">Durant 1999</a>; <a href="./references#CD006495-bbs2-0006" title="GreenH , GibbDM , CompagnucciA , GiacometV , deRossiA , HarperL , et al. A randomized controlled trial of genotypic HIV drug resistance testing in HIV‐1‐infected children: the PERA (PENTA 8) trial. Antiviral Therapy2006;11(7):857‐67. [PUBMED: 17302248] ">Green 2006</a>; <a href="./references#CD006495-bbs2-0007" title="HaubrichRH , KemperCA , HellmannNS , KeiserPH , WittMD , TillesJG , et al. A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575. AIDS (London, England)2005;19(3):295‐302. [PUBMED: 15718840] ">Haubrich 2005</a>; <a href="./references#CD006495-bbs2-0008" title="MeynardJL , VrayM , Morand‐JoubertL , RaceE , DescampsD , PeytavinG , et al. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS (London, England)2002;16(5):727‐36. [PUBMED: 11964529] ">Meynard 2002</a>; <a href="./references#CD006495-bbs2-0009" title="RubiniNPM , BrindeiroPA , BrindeiroRM , LlerenaCA , HertogsK , TanuriA . Clinical value of HIV‐1 genotyping in children and adolescents heavily experiences in antiretroviral therapy. XIV International AIDS Conference. Barcelona, 2002. ">Rubini 2002</a>; <a href="./references#CD006495-bbs2-0010" title="TuralC , RuizL , HoltzerC , SchapiroJ , VicianaP , GonzalezJ , et al. Clinical utility of HIV‐1 genotyping and expert advice: the Havana trial. AIDS (London, England)2002;16(2):209‐18. [PUBMED: 11807305] ">Tural 2002</a>). One study reported time to persistent treatment failure (<a href="./references#CD006495-bbs2-0011" title="WegnerSA , WallaceMR , AronsonNE , TaskerSA , BlazesDL , TammingaC , et al. Long‐term efficacy of routine access to antiretroviral‐resistance testing in HIV type 1‐infected patients: results of the clinical efficacy of resistance testing trial. Clinical Infectious Diseases2004;38(5):723‐30. [PUBMED: 14986258] ">Wegner 2004</a>). </p> </section> <section id="CD006495-sec-0080"> <h5 class="title">Length of follow‐up</h5> <p>The shortest length of follow‐up was 12 weeks (<a href="./references#CD006495-bbs2-0001" title="BaxterJD , MayersDL , WentworthDN , NeatonJD , HooverML , WintersMA , et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS (London, England)2000;14(9):F83‐93. [PUBMED: 10894268] ">Baxter 2000</a>; <a href="./references#CD006495-bbs2-0002" title="CingolaniA , AntinoriA , RizzoMG , MurriR , AmmassariA , BaldiniF , et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS (London, England)2002;16(3):369‐79. [PUBMED: 11834948] ">Cingolani 2002</a>), and the longest was 150 weeks (<a href="./references#CD006495-bbs2-0011" title="WegnerSA , WallaceMR , AronsonNE , TaskerSA , BlazesDL , TammingaC , et al. Long‐term efficacy of routine access to antiretroviral‐resistance testing in HIV type 1‐infected patients: results of the clinical efficacy of resistance testing trial. Clinical Infectious Diseases2004;38(5):723‐30. [PUBMED: 14986258] ">Wegner 2004</a>). One trial ran for 16 weeks (<a href="./references#CD006495-bbs2-0003" title="CohenCJ , HuntS , SensionM , FarthingC , ConantM , JacobsonS , et al. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS (London, England)2002;16(4):579‐88. [PUBMED: 11873001] ">Cohen 2002</a>); three for 24 weeks (<a href="./references#CD006495-bbs2-0005" title="DurantJ , ClevenberghP , HalfonP , DelgiudiceP , PorsinS , SimonetP , et al. Drug‐resistance genotyping in HIV‐1 therapy: the VIRADAPT randomised controlled trial. Lancet (London, England)1999;353(9171):2195‐9. [PUBMED: 10392984] ">Durant 1999</a>; <a href="./references#CD006495-bbs2-0009" title="RubiniNPM , BrindeiroPA , BrindeiroRM , LlerenaCA , HertogsK , TanuriA . Clinical value of HIV‐1 genotyping in children and adolescents heavily experiences in antiretroviral therapy. XIV International AIDS Conference. Barcelona, 2002. ">Rubini 2002</a>; <a href="./references#CD006495-bbs2-0010" title="TuralC , RuizL , HoltzerC , SchapiroJ , VicianaP , GonzalezJ , et al. Clinical utility of HIV‐1 genotyping and expert advice: the Havana trial. AIDS (London, England)2002;16(2):209‐18. [PUBMED: 11807305] ">Tural 2002</a>); one for 36 weeks (<a href="./references#CD006495-bbs2-0008" title="MeynardJL , VrayM , Morand‐JoubertL , RaceE , DescampsD , PeytavinG , et al. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS (London, England)2002;16(5):727‐36. [PUBMED: 11964529] ">Meynard 2002</a>); two for 52 weeks (<a href="./references#CD006495-bbs2-0004" title="Evaluation of Resistance Assays (ERA) Trial Investigators. A randomized controlled trial of the clinical utility of genotypic resistance testing in patients with limited prior exposure to antiretroviral drugs. HIV Clinical Trials2005;6(4):183‐6. [PUBMED: 16214734] ">Dunn 2005</a>; <a href="./references#CD006495-bbs2-0007" title="HaubrichRH , KemperCA , HellmannNS , KeiserPH , WittMD , TillesJG , et al. A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575. AIDS (London, England)2005;19(3):295‐302. [PUBMED: 15718840] ">Haubrich 2005</a>); and one for 96 weeks (<a href="./references#CD006495-bbs2-0006" title="GreenH , GibbDM , CompagnucciA , GiacometV , deRossiA , HarperL , et al. A randomized controlled trial of genotypic HIV drug resistance testing in HIV‐1‐infected children: the PERA (PENTA 8) trial. Antiviral Therapy2006;11(7):857‐67. [PUBMED: 17302248] ">Green 2006</a>). The median follow‐up time was 24 weeks (quartile 1 = 16; quartile 3 = 52). </p> <p>We have provided further details on the included studies in an additional table (<a href="#CD006495-tbl-0002">Table 1</a>). </p> <div class="table" id="CD006495-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Additional characteristics of included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial ID (acronym)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Location</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Exposure criteria</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Definition of virological failure at entry</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Type of resistance testing compared to control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Primary virological success cutoff point (copies/mL)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Expert opinion</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of follow‐up (weeks)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006495-bbs2-0001" title="BaxterJD , MayersDL , WentworthDN , NeatonJD , HooverML , WintersMA , et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS (London, England)2000;14(9):F83‐93. [PUBMED: 10894268] ">Baxter 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A combination antiretroviral regimen containing a single PI (indinavir, nelfinavir, saquinavir, or </p> <p>ritonavir) and 2 NRTIs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Four conditions: (1) patient taking a current triple‐drug regimen for at least 16 weeks; (2) a locally determined screening HIV‐1‐RNA level &gt; 20,000 copies/mL by the Roche Amplicor HIV‐1 assay or &gt; 10,000 copies/mL by the Chiron branched chain (bDNA) assay within 6 weeks before a required baseline visit; (3) documentation that the screening HIV‐1‐RNA level was 3‐fold greater than the nadir HIV‐1‐RNA level while on the triple‐drug regimen, or that the nadir was &lt; 500 copies/mL; and (4) a centrally determined HIV‐1‐RNA level &gt; 5000 copies/mL by the Chiron 2.0 bDNA assay using plasma collected at the baseline visit </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Genotype</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006495-bbs2-0002" title="CingolaniA , AntinoriA , RizzoMG , MurriR , AmmassariA , BaldiniF , et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS (London, England)2002;16(3):369‐79. [PUBMED: 11834948] ">Cingolani 2002</a> (ARGENTA) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At least 2 months on a highly active</p> <p>antiretroviral regimen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two conditions: (1) plasma viral load &gt; 2000 copies/mL in at least two consecutive determinations; or (2) &lt; 1 log reduction in HIV RNA more than 2 months after the start of the last regimen </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Genotype</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006495-bbs2-0003" title="CohenCJ , HuntS , SensionM , FarthingC , ConantM , JacobsonS , et al. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS (London, England)2002;16(4):579‐88. [PUBMED: 11873001] ">Cohen 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At least 2 NRTIs and only one PI, taken for at least</p> <p>1 month before screening</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐1‐RNA plasma levels ≥ 2000 copies/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phenotype</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006495-bbs2-0004" title="Evaluation of Resistance Assays (ERA) Trial Investigators. A randomized controlled trial of the clinical utility of genotypic resistance testing in patients with limited prior exposure to antiretroviral drugs. HIV Clinical Trials2005;6(4):183‐6. [PUBMED: 16214734] ">Dunn 2005</a> (ERA) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>On ART</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Most recent HIV‐1‐RNA plasma viral load (VL) exceeding 2000 copies/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Genotype</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006495-bbs2-0005" title="DurantJ , ClevenberghP , HalfonP , DelgiudiceP , PorsinS , SimonetP , et al. Drug‐resistance genotyping in HIV‐1 therapy: the VIRADAPT randomised controlled trial. Lancet (London, England)1999;353(9171):2195‐9. [PUBMED: 10392984] ">Durant 1999</a> (VIRADAPT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>France</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At least 6 months of treatment with nucleoside</p> <p>analogues and at least 3 months of treatment with a protease</p> <p>inhibitor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Plasma HIV‐1‐RNA &gt; 10,000 copies/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Genotype</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006495-bbs2-0006" title="GreenH , GibbDM , CompagnucciA , GiacometV , deRossiA , HarperL , et al. A randomized controlled trial of genotypic HIV drug resistance testing in HIV‐1‐infected children: the PERA (PENTA 8) trial. Antiviral Therapy2006;11(7):857‐67. [PUBMED: 17302248] ">Green 2006</a> (PERA (PENTA 8)) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy, Brazil, UK, Spain, Germany, Portugal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Greater exposure than 2 or 3 nucleoside reverse</p> <p>transcriptase inhibitors (NRTIs) for &lt; 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Most recent HIV‐1‐RNA plasma viral load &gt; 2000 copies/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Genotype</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006495-bbs2-0007" title="HaubrichRH , KemperCA , HellmannNS , KeiserPH , WittMD , TillesJG , et al. A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575. AIDS (London, England)2005;19(3):295‐302. [PUBMED: 15718840] ">Haubrich 2005</a> (CCTG) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At least</p> <p>6 months of previous ART, exposure to no more than</p> <p>2 prior protease inhibitors (PIs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV RNA &gt; 400 copies/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phenotype</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006495-bbs2-0008" title="MeynardJL , VrayM , Morand‐JoubertL , RaceE , DescampsD , PeytavinG , et al. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS (London, England)2002;16(5):727‐36. [PUBMED: 11964529] ">Meynard 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Previous exposure to at least 1 protease inhibitor (PI)</p> <p>for at least 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Plasma HIV‐1‐RNA &gt; 1000 copies/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Genotype and Phenotype</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006495-bbs2-0009" title="RubiniNPM , BrindeiroPA , BrindeiroRM , LlerenaCA , HertogsK , TanuriA . Clinical value of HIV‐1 genotyping in children and adolescents heavily experiences in antiretroviral therapy. XIV International AIDS Conference. Barcelona, 2002. ">Rubini 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Brazil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Previous exposure to at least 2 ART regimens, with failure of their current therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Genotype</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006495-bbs2-0010" title="TuralC , RuizL , HoltzerC , SchapiroJ , VicianaP , GonzalezJ , et al. Clinical utility of HIV‐1 genotyping and expert advice: the Havana trial. AIDS (London, England)2002;16(2):209‐18. [PUBMED: 11807305] ">Tural 2002</a> (Havana) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Spain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stable antiretroviral</p> <p>therapy combination for longer than 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Plasma HIV‐1‐RNA ≥ 1000 copies/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Genotype</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006495-bbs2-0011" title="WegnerSA , WallaceMR , AronsonNE , TaskerSA , BlazesDL , TammingaC , et al. Long‐term efficacy of routine access to antiretroviral‐resistance testing in HIV type 1‐infected patients: results of the clinical efficacy of resistance testing trial. Clinical Infectious Diseases2004;38(5):723‐30. [PUBMED: 14986258] ">Wegner 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Receiving a</p> <p>stable ART regimen containing ≥ 2 drugs for at least 8 weeks</p> <p>before randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VL &gt; 3.0 log₁₀ copies/mL concomitant with ≥ 1 of the following conditions: &lt; 1.0 log₁₀ reduction in VL 4 weeks after start of a therapy regimen, failure to suppress VL to &lt; 200 copies/mL 6 weeks after start of therapy, detection of plasma VL &gt; 3.0 log₁₀ copies/mL after initial suppression to &lt; 200 copies/mL, or increase of &gt; 0.5 log₁₀ copies/mL (to &gt; 3.0 log₁₀ copies/mL) from the nadir VL that could not be directly attributed to vaccination or intercurrent illness </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Genotype and Phenotype</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Abbreviations: ART: antiretroviral therapy; bDNA: branched DNA assay; NA: not applicable; NRTI: nucleoside reverse transcriptase inhibitor; PI: protease inhibitor; VL: viral load. </p> </div> </div> </section> </section> <section id="CD006495-sec-0081"> <h4 class="title">Excluded studies</h4> <p>We excluded 19 potentially relevant studies and summarized these in the <a href="./references#CD006495-sec-0132" title="">Characteristics of excluded studies</a> table. Five of these studies used genotypic guided therapy in both study arms (<a href="./references#CD006495-bbs2-0014" title="BossiP , PeytavinG , Ait‐MohandH , DelaugerreC , KtorzaN , ParisL , et al. GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy. HIV Medicine2004;5:352‐9. ">Bossi 2004</a>; <a href="./references#CD006495-bbs2-0015" title="ClevenberghP , DurantJ , HalfonP , delGiudiceP , MondainV , MontagneN , et al. Persisting long‐term benefit of genotype‐guided treatment for HIV‐infected patients failing HAART. The Viradapt Study: week 48 follow‐up. Antiviral Therapy2000;5:65‐70. ">Clevenbergh 2000</a>; <a href="./references#CD006495-bbs2-0019" title="DunnD . A randomized controlled trial of the value of phenotypic testing in addition to genotypic testing for HIV drug resistance. Journal of Acquired Immune Deficiency Syndromes2005;38:553‐9. ">Dunn 2005a</a>; <a href="./references#CD006495-bbs2-0021" title="GianottiN , MondinoV , RossiMC , ChiesaE , MezzaromaI , LadisaN , et al. Comparison of a rule‐based algorithm with a phenotype‐based algorithm for the interpretation of HIV genotypes in guiding salvage regimens in HIV‐infected patients by a randomized clinical trial: the mutations and salvage study. Clinical Infectious Diseases2006; Vol. 42:1470‐80. ">Gianotti 2006</a>; <a href="./references#CD006495-bbs2-0022" title="HalesG , BirchC , CroweS , WorkmanC , HoyJF , LawMG , et al. A randomised trial comparing genotypic and virtual phenotypic interpretation of HIV drug resistance: the CREST study. PLoS Clinical Trials2006; Vol. 1:e18. ">Hales 2006</a>); and four compared genotypic versus phenotypic testing and included no control arm (<a href="./references#CD006495-bbs2-0025" title="MazzottaF , Lo CaputoS , TortiC , TinelliC , PierottiP , CastelliF , et al. Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48‐week follow‐up of the Genotipo‐Fenotipo di Resistenza (GenPheRex) trial. Journal of Acquired Immune Deficiency Syndromes2003;32:268‐80. ">Mazzotta 2003</a>; <a href="./references#CD006495-bbs2-0027" title="Perez‐EliasMJ , Garcia‐ArataI , MunozV , SantosI , SanzJ , AbrairaV , et al. Phenotype or virtual phenotype for choosing antiretroviral therapy after failure: a prospective, randomized study. Antiviral Therapy2003;8:577‐84. ">Perez‐Elias 2003</a>; <a href="./references#CD006495-bbs2-0028" title="SaracinoA , MonnoL , LocaputoS , TortiC , ScudellerL , LadisaN , et al. Selection of antiretroviral therapy guided by genotypic or phenotypic resistance testing: an open‐label, randomized, multicenter study (PhenGen). Journal of Acquired Immune Deficiency Syndromes2004;37:1587‐98. ">Saracino 2004</a>; <a href="./references#CD006495-bbs2-0029" title="TortiC , Quiros‐RoldanE , RegazziM , DeLucaA , MazzottaF , AntinoriA , et al. A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules‐based or phenotype‐driven HIV‐1 genotypic drug‐resistance interpretation with or without concentration‐controlled intervention: the resistance and dosage adapted regimens (RADAR) study. Clinical Infectious Diseases2005;40:1828‐36. ">Torti 2005</a>). One was a simulation study (<a href="./references#CD006495-bbs2-0023" title="LorenzanaSB , HughesMD , GrinsztejnB , CollierAC , LuzPM , FreedbergKA , et al. Genotype assays and third‐line ART in resource‐limited settings: a simulation and cost‐effectiveness analysis of a planned clinical trial. AIDS2012;26:1083‐93. ">Lorenzana 2012</a>). Another compared strategies to interpret HIV genotypic resistance tests (<a href="./references#CD006495-bbs2-0024" title="MaggioloF , AiroldiM , CallegaroA , RipamontiD , GregisG , QuinzanG , et al. Prediction of virologic outcome of salvage antiretroviral treatment by different systems for interpreting genotypic HIV drug resistance. Journal of the International Association of Physicians in AIDS Care2007;6:87‐93. ">Maggiolo 2007</a>). Two were cross‐sectional studies of drug resistance rates (<a href="./references#CD006495-bbs2-0026" title="PereH , CharpentierC , MbelessoP , DandyM , MattaM , MoussaS , et al. Virological response and resistance profiles after 24 months of first‐line antiretroviral treatment in adults living in Bangui, central African Republic. AIDS Research and Human Retroviruses2012;28:315‐23. ">Pere 2012</a>; <a href="./references#CD006495-bbs2-0030" title="VergneL , KaneCT , LaurentC , DiakhateN , Ngom GueyeNF , GueyePM , et al. Low rate of genotypic HIV‐1 drug‐resistant strains in the Senegalese government initiative of access to antiretroviral therapy. AIDS2003;17:S31‐8. ">Vergne 2003</a>); three were secondary analyses of included studies with no additional outcome information (<a href="./references#CD006495-bbs2-0016" title="ClevenberghP , GarraffoR , DurantJ , DellamonicaP . PharmAdapt: a randomized prospective study to evaluate the benefit of therapeutic monitoring of protease inhibitors: 12 week results. AIDS2002;16:2311‐5. ">Clevenbergh 2002</a>; <a href="./references#CD006495-bbs2-0017" title="DeLucaA , DiGiambenedettoS , CingolaniA , BacarelliA , AmmassariA , CaudaR . Three‐year clinical outcomes of resistance genotyping and expert advice: extended follow‐up of the Argenta trial. Antiviral Therapy2006;11:321‐7. ">De Luca 2006</a>; <a href="./references#CD006495-bbs2-0020" title="DurantJ , ClevenberghP , GarraffoR , HalfonP , IcardS , DelGiudiceP , et al. Importance of protease inhibitor plasma levels in HIV‐infected patients treated with genotypic‐guided therapy: pharmacological data from the Viradapt Study. AIDS2000;14:1333‐9. ">Durant 2000</a>); two did not include any relevant intervention arm (<a href="./references#CD006495-bbs2-0013" title="BonjochA , BuzonMJ , LlibreJM , NegredoE , PuigJ , Perez‐AlvarezN , et al. Transient treatment exclusively containing nucleoside analogue reverse transcriptase inhibitors in highly antiretroviral‐experienced patients preserves viral benefit when a fully active therapy was initiated. HIV Clinical Trials2008;9:387‐98. ">Bonjoch 2008</a>; <a href="./references#CD006495-bbs2-0018" title="DemeterLM , MukherjeeAL , DiFrancescoR , JiangH , DiCenzoR , BastowB , et al. The design and implementation of A5146, a prospective trial assessing the utility of therapeutic drug monitoring using an inhibitory quotient in antiretroviral‐experienced HIV‐infected patients. HIV Clinical Trials2008;9:61‐72. ">Demeter 2008</a>); and one was a retrospective evaluation of an RCT (<a href="./references#CD006495-bbs2-0012" title="BadriSM , AdeyemiOM , MaxBE , ZagorskiBM , BarkerDE . How does expert advice impact genotypic resistance testing in clinical practice?. Clinical Infectious Diseases2003;37:708‐13. ">Badri 2003</a>). </p> </section> </section> <section id="CD006495-sec-0082"> <h3 class="title">Risk of bias in included studies</h3> <p>We assessed the risk of bias of each included study using the Cochrane ‘Risk of bias' assessment tool (<a href="./appendices#CD006495-sec-0123">Appendix 4</a>). We assessed risk of bias in individual trials across seven domains: sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessor, incomplete outcome data, selective outcome reporting, and other potential biases. We summarized these into one overall assessment of risk of bias. See the ‘Risk of bias' summary in <a href="#CD006495-fig-0002">Figure 2</a> and the ‘Risk of bias' graph in <a href="#CD006495-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD006495-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="‘Risk of bias' summary: review authors' judgements about each ‘Risk of bias' item for each included study." data-id="CD006495-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_n/nCD006495-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>‘Risk of bias' summary: review authors' judgements about each ‘Risk of bias' item for each included study. </p> </div> </div> </div> <div class="figure" id="CD006495-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="‘Risk of bias' graph: review authors' judgements about each ‘Risk of bias' item presented as percentages across all included studies." data-id="CD006495-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_n/nCD006495-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>‘Risk of bias' graph: review authors' judgements about each ‘Risk of bias' item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD006495-sec-0083"> <h4 class="title">Allocation</h4> <section id="CD006495-sec-0084"> <h5 class="title">Generation of allocation sequence</h5> <p>Only four studies reported how the allocation sequence was generated (<a href="./references#CD006495-bbs2-0001" title="BaxterJD , MayersDL , WentworthDN , NeatonJD , HooverML , WintersMA , et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS (London, England)2000;14(9):F83‐93. [PUBMED: 10894268] ">Baxter 2000</a>; <a href="./references#CD006495-bbs2-0003" title="CohenCJ , HuntS , SensionM , FarthingC , ConantM , JacobsonS , et al. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS (London, England)2002;16(4):579‐88. [PUBMED: 11873001] ">Cohen 2002</a>; <a href="./references#CD006495-bbs2-0005" title="DurantJ , ClevenberghP , HalfonP , DelgiudiceP , PorsinS , SimonetP , et al. Drug‐resistance genotyping in HIV‐1 therapy: the VIRADAPT randomised controlled trial. Lancet (London, England)1999;353(9171):2195‐9. [PUBMED: 10392984] ">Durant 1999</a>; <a href="./references#CD006495-bbs2-0006" title="GreenH , GibbDM , CompagnucciA , GiacometV , deRossiA , HarperL , et al. A randomized controlled trial of genotypic HIV drug resistance testing in HIV‐1‐infected children: the PERA (PENTA 8) trial. Antiviral Therapy2006;11(7):857‐67. [PUBMED: 17302248] ">Green 2006</a>). For all other studies, the method of sequence generation was unclear (<a href="./references#CD006495-bbs2-0002" title="CingolaniA , AntinoriA , RizzoMG , MurriR , AmmassariA , BaldiniF , et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS (London, England)2002;16(3):369‐79. [PUBMED: 11834948] ">Cingolani 2002</a>; <a href="./references#CD006495-bbs2-0004" title="Evaluation of Resistance Assays (ERA) Trial Investigators. A randomized controlled trial of the clinical utility of genotypic resistance testing in patients with limited prior exposure to antiretroviral drugs. HIV Clinical Trials2005;6(4):183‐6. [PUBMED: 16214734] ">Dunn 2005</a>; <a href="./references#CD006495-bbs2-0007" title="HaubrichRH , KemperCA , HellmannNS , KeiserPH , WittMD , TillesJG , et al. A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575. AIDS (London, England)2005;19(3):295‐302. [PUBMED: 15718840] ">Haubrich 2005</a>; <a href="./references#CD006495-bbs2-0008" title="MeynardJL , VrayM , Morand‐JoubertL , RaceE , DescampsD , PeytavinG , et al. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS (London, England)2002;16(5):727‐36. [PUBMED: 11964529] ">Meynard 2002</a>; <a href="./references#CD006495-bbs2-0009" title="RubiniNPM , BrindeiroPA , BrindeiroRM , LlerenaCA , HertogsK , TanuriA . Clinical value of HIV‐1 genotyping in children and adolescents heavily experiences in antiretroviral therapy. XIV International AIDS Conference. Barcelona, 2002. ">Rubini 2002</a>; <a href="./references#CD006495-bbs2-0010" title="TuralC , RuizL , HoltzerC , SchapiroJ , VicianaP , GonzalezJ , et al. Clinical utility of HIV‐1 genotyping and expert advice: the Havana trial. AIDS (London, England)2002;16(2):209‐18. [PUBMED: 11807305] ">Tural 2002</a>; <a href="./references#CD006495-bbs2-0011" title="WegnerSA , WallaceMR , AronsonNE , TaskerSA , BlazesDL , TammingaC , et al. Long‐term efficacy of routine access to antiretroviral‐resistance testing in HIV type 1‐infected patients: results of the clinical efficacy of resistance testing trial. Clinical Infectious Diseases2004;38(5):723‐30. [PUBMED: 14986258] ">Wegner 2004</a>). </p> </section> <section id="CD006495-sec-0085"> <h5 class="title">Allocation concealment</h5> <p>Eight studies reported appropriate methods of allocation concealment (<a href="./references#CD006495-bbs2-0001" title="BaxterJD , MayersDL , WentworthDN , NeatonJD , HooverML , WintersMA , et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS (London, England)2000;14(9):F83‐93. [PUBMED: 10894268] ">Baxter 2000</a>; <a href="./references#CD006495-bbs2-0003" title="CohenCJ , HuntS , SensionM , FarthingC , ConantM , JacobsonS , et al. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS (London, England)2002;16(4):579‐88. [PUBMED: 11873001] ">Cohen 2002</a>; <a href="./references#CD006495-bbs2-0005" title="DurantJ , ClevenberghP , HalfonP , DelgiudiceP , PorsinS , SimonetP , et al. Drug‐resistance genotyping in HIV‐1 therapy: the VIRADAPT randomised controlled trial. Lancet (London, England)1999;353(9171):2195‐9. [PUBMED: 10392984] ">Durant 1999</a>; <a href="./references#CD006495-bbs2-0006" title="GreenH , GibbDM , CompagnucciA , GiacometV , deRossiA , HarperL , et al. A randomized controlled trial of genotypic HIV drug resistance testing in HIV‐1‐infected children: the PERA (PENTA 8) trial. Antiviral Therapy2006;11(7):857‐67. [PUBMED: 17302248] ">Green 2006</a>; <a href="./references#CD006495-bbs2-0007" title="HaubrichRH , KemperCA , HellmannNS , KeiserPH , WittMD , TillesJG , et al. A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575. AIDS (London, England)2005;19(3):295‐302. [PUBMED: 15718840] ">Haubrich 2005</a>; <a href="./references#CD006495-bbs2-0008" title="MeynardJL , VrayM , Morand‐JoubertL , RaceE , DescampsD , PeytavinG , et al. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS (London, England)2002;16(5):727‐36. [PUBMED: 11964529] ">Meynard 2002</a>; <a href="./references#CD006495-bbs2-0010" title="TuralC , RuizL , HoltzerC , SchapiroJ , VicianaP , GonzalezJ , et al. Clinical utility of HIV‐1 genotyping and expert advice: the Havana trial. AIDS (London, England)2002;16(2):209‐18. [PUBMED: 11807305] ">Tural 2002</a>; <a href="./references#CD006495-bbs2-0011" title="WegnerSA , WallaceMR , AronsonNE , TaskerSA , BlazesDL , TammingaC , et al. Long‐term efficacy of routine access to antiretroviral‐resistance testing in HIV type 1‐infected patients: results of the clinical efficacy of resistance testing trial. Clinical Infectious Diseases2004;38(5):723‐30. [PUBMED: 14986258] ">Wegner 2004</a>). For the remaining three studies, allocation concealment was unclear (<a href="./references#CD006495-bbs2-0002" title="CingolaniA , AntinoriA , RizzoMG , MurriR , AmmassariA , BaldiniF , et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS (London, England)2002;16(3):369‐79. [PUBMED: 11834948] ">Cingolani 2002</a>; <a href="./references#CD006495-bbs2-0004" title="Evaluation of Resistance Assays (ERA) Trial Investigators. A randomized controlled trial of the clinical utility of genotypic resistance testing in patients with limited prior exposure to antiretroviral drugs. HIV Clinical Trials2005;6(4):183‐6. [PUBMED: 16214734] ">Dunn 2005</a>; <a href="./references#CD006495-bbs2-0009" title="RubiniNPM , BrindeiroPA , BrindeiroRM , LlerenaCA , HertogsK , TanuriA . Clinical value of HIV‐1 genotyping in children and adolescents heavily experiences in antiretroviral therapy. XIV International AIDS Conference. Barcelona, 2002. ">Rubini 2002</a>). </p> </section> </section> <section id="CD006495-sec-0086"> <h4 class="title">Blinding of participants and personnel</h4> <p>Nine trials were reported as open‐label or not blinded (<a href="./references#CD006495-bbs2-0002" title="CingolaniA , AntinoriA , RizzoMG , MurriR , AmmassariA , BaldiniF , et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS (London, England)2002;16(3):369‐79. [PUBMED: 11834948] ">Cingolani 2002</a>; <a href="./references#CD006495-bbs2-0003" title="CohenCJ , HuntS , SensionM , FarthingC , ConantM , JacobsonS , et al. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS (London, England)2002;16(4):579‐88. [PUBMED: 11873001] ">Cohen 2002</a>; <a href="./references#CD006495-bbs2-0004" title="Evaluation of Resistance Assays (ERA) Trial Investigators. A randomized controlled trial of the clinical utility of genotypic resistance testing in patients with limited prior exposure to antiretroviral drugs. HIV Clinical Trials2005;6(4):183‐6. [PUBMED: 16214734] ">Dunn 2005</a>; <a href="./references#CD006495-bbs2-0005" title="DurantJ , ClevenberghP , HalfonP , DelgiudiceP , PorsinS , SimonetP , et al. Drug‐resistance genotyping in HIV‐1 therapy: the VIRADAPT randomised controlled trial. Lancet (London, England)1999;353(9171):2195‐9. [PUBMED: 10392984] ">Durant 1999</a>; <a href="./references#CD006495-bbs2-0006" title="GreenH , GibbDM , CompagnucciA , GiacometV , deRossiA , HarperL , et al. A randomized controlled trial of genotypic HIV drug resistance testing in HIV‐1‐infected children: the PERA (PENTA 8) trial. Antiviral Therapy2006;11(7):857‐67. [PUBMED: 17302248] ">Green 2006</a>; <a href="./references#CD006495-bbs2-0007" title="HaubrichRH , KemperCA , HellmannNS , KeiserPH , WittMD , TillesJG , et al. A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575. AIDS (London, England)2005;19(3):295‐302. [PUBMED: 15718840] ">Haubrich 2005</a>; <a href="./references#CD006495-bbs2-0008" title="MeynardJL , VrayM , Morand‐JoubertL , RaceE , DescampsD , PeytavinG , et al. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS (London, England)2002;16(5):727‐36. [PUBMED: 11964529] ">Meynard 2002</a>; <a href="./references#CD006495-bbs2-0010" title="TuralC , RuizL , HoltzerC , SchapiroJ , VicianaP , GonzalezJ , et al. Clinical utility of HIV‐1 genotyping and expert advice: the Havana trial. AIDS (London, England)2002;16(2):209‐18. [PUBMED: 11807305] ">Tural 2002</a>; <a href="./references#CD006495-bbs2-0011" title="WegnerSA , WallaceMR , AronsonNE , TaskerSA , BlazesDL , TammingaC , et al. Long‐term efficacy of routine access to antiretroviral‐resistance testing in HIV type 1‐infected patients: results of the clinical efficacy of resistance testing trial. Clinical Infectious Diseases2004;38(5):723‐30. [PUBMED: 14986258] ">Wegner 2004</a>), and two studies did not mention blinding (<a href="./references#CD006495-bbs2-0001" title="BaxterJD , MayersDL , WentworthDN , NeatonJD , HooverML , WintersMA , et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS (London, England)2000;14(9):F83‐93. [PUBMED: 10894268] ">Baxter 2000</a>; <a href="./references#CD006495-bbs2-0009" title="RubiniNPM , BrindeiroPA , BrindeiroRM , LlerenaCA , HertogsK , TanuriA . Clinical value of HIV‐1 genotyping in children and adolescents heavily experiences in antiretroviral therapy. XIV International AIDS Conference. Barcelona, 2002. ">Rubini 2002</a>). Given the nature of the intervention, we judged that lack of blinding was unlikely to introduce bias. </p> </section> <section id="CD006495-sec-0087"> <h4 class="title">Blinding of outcome assessors</h4> <p>No studies reported blinding of outcome assessors. Given the nature of measured outcomes, we judged that lack of blinding was unlikely to introduce bias. </p> </section> <section id="CD006495-sec-0088"> <h4 class="title">Incomplete outcome data</h4> <p>Eight studies reported levels and causes of attrition. These were balanced between groups, and levels of attrition were low (&lt; 20%; <a href="./references#CD006495-bbs2-0001" title="BaxterJD , MayersDL , WentworthDN , NeatonJD , HooverML , WintersMA , et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS (London, England)2000;14(9):F83‐93. [PUBMED: 10894268] ">Baxter 2000</a>; <a href="./references#CD006495-bbs2-0002" title="CingolaniA , AntinoriA , RizzoMG , MurriR , AmmassariA , BaldiniF , et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS (London, England)2002;16(3):369‐79. [PUBMED: 11834948] ">Cingolani 2002</a>; <a href="./references#CD006495-bbs2-0003" title="CohenCJ , HuntS , SensionM , FarthingC , ConantM , JacobsonS , et al. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS (London, England)2002;16(4):579‐88. [PUBMED: 11873001] ">Cohen 2002</a>; <a href="./references#CD006495-bbs2-0004" title="Evaluation of Resistance Assays (ERA) Trial Investigators. A randomized controlled trial of the clinical utility of genotypic resistance testing in patients with limited prior exposure to antiretroviral drugs. HIV Clinical Trials2005;6(4):183‐6. [PUBMED: 16214734] ">Dunn 2005</a>; <a href="./references#CD006495-bbs2-0005" title="DurantJ , ClevenberghP , HalfonP , DelgiudiceP , PorsinS , SimonetP , et al. Drug‐resistance genotyping in HIV‐1 therapy: the VIRADAPT randomised controlled trial. Lancet (London, England)1999;353(9171):2195‐9. [PUBMED: 10392984] ">Durant 1999</a>; <a href="./references#CD006495-bbs2-0006" title="GreenH , GibbDM , CompagnucciA , GiacometV , deRossiA , HarperL , et al. A randomized controlled trial of genotypic HIV drug resistance testing in HIV‐1‐infected children: the PERA (PENTA 8) trial. Antiviral Therapy2006;11(7):857‐67. [PUBMED: 17302248] ">Green 2006</a>; <a href="./references#CD006495-bbs2-0008" title="MeynardJL , VrayM , Morand‐JoubertL , RaceE , DescampsD , PeytavinG , et al. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS (London, England)2002;16(5):727‐36. [PUBMED: 11964529] ">Meynard 2002</a>; <a href="./references#CD006495-bbs2-0010" title="TuralC , RuizL , HoltzerC , SchapiroJ , VicianaP , GonzalezJ , et al. Clinical utility of HIV‐1 genotyping and expert advice: the Havana trial. AIDS (London, England)2002;16(2):209‐18. [PUBMED: 11807305] ">Tural 2002</a>). We judged these studies to be at low risk of bias. One study was at high risk of bias for providing incomplete outcome data (<a href="./references#CD006495-bbs2-0011" title="WegnerSA , WallaceMR , AronsonNE , TaskerSA , BlazesDL , TammingaC , et al. Long‐term efficacy of routine access to antiretroviral‐resistance testing in HIV type 1‐infected patients: results of the clinical efficacy of resistance testing trial. Clinical Infectious Diseases2004;38(5):723‐30. [PUBMED: 14986258] ">Wegner 2004</a>), and another study was at unclear risk of bias (<a href="./references#CD006495-bbs2-0007" title="HaubrichRH , KemperCA , HellmannNS , KeiserPH , WittMD , TillesJG , et al. A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575. AIDS (London, England)2005;19(3):295‐302. [PUBMED: 15718840] ">Haubrich 2005</a>). <a href="./references#CD006495-bbs2-0009" title="RubiniNPM , BrindeiroPA , BrindeiroRM , LlerenaCA , HertogsK , TanuriA . Clinical value of HIV‐1 genotyping in children and adolescents heavily experiences in antiretroviral therapy. XIV International AIDS Conference. Barcelona, 2002. ">Rubini 2002</a> did not report exclusions by group. </p> </section> <section id="CD006495-sec-0089"> <h4 class="title">Selective reporting</h4> <p>Ten studies reported all outcomes that could reasonably be expected (<a href="./references#CD006495-bbs2-0001" title="BaxterJD , MayersDL , WentworthDN , NeatonJD , HooverML , WintersMA , et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS (London, England)2000;14(9):F83‐93. [PUBMED: 10894268] ">Baxter 2000</a>; <a href="./references#CD006495-bbs2-0002" title="CingolaniA , AntinoriA , RizzoMG , MurriR , AmmassariA , BaldiniF , et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS (London, England)2002;16(3):369‐79. [PUBMED: 11834948] ">Cingolani 2002</a>; <a href="./references#CD006495-bbs2-0003" title="CohenCJ , HuntS , SensionM , FarthingC , ConantM , JacobsonS , et al. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS (London, England)2002;16(4):579‐88. [PUBMED: 11873001] ">Cohen 2002</a>; <a href="./references#CD006495-bbs2-0004" title="Evaluation of Resistance Assays (ERA) Trial Investigators. A randomized controlled trial of the clinical utility of genotypic resistance testing in patients with limited prior exposure to antiretroviral drugs. HIV Clinical Trials2005;6(4):183‐6. [PUBMED: 16214734] ">Dunn 2005</a>; <a href="./references#CD006495-bbs2-0005" title="DurantJ , ClevenberghP , HalfonP , DelgiudiceP , PorsinS , SimonetP , et al. Drug‐resistance genotyping in HIV‐1 therapy: the VIRADAPT randomised controlled trial. Lancet (London, England)1999;353(9171):2195‐9. [PUBMED: 10392984] ">Durant 1999</a>; <a href="./references#CD006495-bbs2-0006" title="GreenH , GibbDM , CompagnucciA , GiacometV , deRossiA , HarperL , et al. A randomized controlled trial of genotypic HIV drug resistance testing in HIV‐1‐infected children: the PERA (PENTA 8) trial. Antiviral Therapy2006;11(7):857‐67. [PUBMED: 17302248] ">Green 2006</a>; <a href="./references#CD006495-bbs2-0007" title="HaubrichRH , KemperCA , HellmannNS , KeiserPH , WittMD , TillesJG , et al. A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575. AIDS (London, England)2005;19(3):295‐302. [PUBMED: 15718840] ">Haubrich 2005</a>; <a href="./references#CD006495-bbs2-0008" title="MeynardJL , VrayM , Morand‐JoubertL , RaceE , DescampsD , PeytavinG , et al. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS (London, England)2002;16(5):727‐36. [PUBMED: 11964529] ">Meynard 2002</a>; <a href="./references#CD006495-bbs2-0009" title="RubiniNPM , BrindeiroPA , BrindeiroRM , LlerenaCA , HertogsK , TanuriA . Clinical value of HIV‐1 genotyping in children and adolescents heavily experiences in antiretroviral therapy. XIV International AIDS Conference. Barcelona, 2002. ">Rubini 2002</a>; <a href="./references#CD006495-bbs2-0010" title="TuralC , RuizL , HoltzerC , SchapiroJ , VicianaP , GonzalezJ , et al. Clinical utility of HIV‐1 genotyping and expert advice: the Havana trial. AIDS (London, England)2002;16(2):209‐18. [PUBMED: 11807305] ">Tural 2002</a>). We judged these studies to be at low risk of bias for selective reporting. One study was at high risk of bias for selective reporting (<a href="./references#CD006495-bbs2-0011" title="WegnerSA , WallaceMR , AronsonNE , TaskerSA , BlazesDL , TammingaC , et al. Long‐term efficacy of routine access to antiretroviral‐resistance testing in HIV type 1‐infected patients: results of the clinical efficacy of resistance testing trial. Clinical Infectious Diseases2004;38(5):723‐30. [PUBMED: 14986258] ">Wegner 2004</a>). </p> </section> <section id="CD006495-sec-0090"> <h4 class="title">Other potential sources of bias</h4> <section id="CD006495-sec-0091"> <h5 class="title">Funding</h5> <p>Eight studies reported government or private funding (<a href="./references#CD006495-bbs2-0001" title="BaxterJD , MayersDL , WentworthDN , NeatonJD , HooverML , WintersMA , et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS (London, England)2000;14(9):F83‐93. [PUBMED: 10894268] ">Baxter 2000</a>; <a href="./references#CD006495-bbs2-0002" title="CingolaniA , AntinoriA , RizzoMG , MurriR , AmmassariA , BaldiniF , et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS (London, England)2002;16(3):369‐79. [PUBMED: 11834948] ">Cingolani 2002</a>; <a href="./references#CD006495-bbs2-0004" title="Evaluation of Resistance Assays (ERA) Trial Investigators. A randomized controlled trial of the clinical utility of genotypic resistance testing in patients with limited prior exposure to antiretroviral drugs. HIV Clinical Trials2005;6(4):183‐6. [PUBMED: 16214734] ">Dunn 2005</a>; <a href="./references#CD006495-bbs2-0006" title="GreenH , GibbDM , CompagnucciA , GiacometV , deRossiA , HarperL , et al. A randomized controlled trial of genotypic HIV drug resistance testing in HIV‐1‐infected children: the PERA (PENTA 8) trial. Antiviral Therapy2006;11(7):857‐67. [PUBMED: 17302248] ">Green 2006</a>; <a href="./references#CD006495-bbs2-0007" title="HaubrichRH , KemperCA , HellmannNS , KeiserPH , WittMD , TillesJG , et al. A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575. AIDS (London, England)2005;19(3):295‐302. [PUBMED: 15718840] ">Haubrich 2005</a>; <a href="./references#CD006495-bbs2-0008" title="MeynardJL , VrayM , Morand‐JoubertL , RaceE , DescampsD , PeytavinG , et al. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS (London, England)2002;16(5):727‐36. [PUBMED: 11964529] ">Meynard 2002</a>; <a href="./references#CD006495-bbs2-0010" title="TuralC , RuizL , HoltzerC , SchapiroJ , VicianaP , GonzalezJ , et al. Clinical utility of HIV‐1 genotyping and expert advice: the Havana trial. AIDS (London, England)2002;16(2):209‐18. [PUBMED: 11807305] ">Tural 2002</a>; <a href="./references#CD006495-bbs2-0011" title="WegnerSA , WallaceMR , AronsonNE , TaskerSA , BlazesDL , TammingaC , et al. Long‐term efficacy of routine access to antiretroviral‐resistance testing in HIV type 1‐infected patients: results of the clinical efficacy of resistance testing trial. Clinical Infectious Diseases2004;38(5):723‐30. [PUBMED: 14986258] ">Wegner 2004</a>). We judged these studies to be at low risk of bias. One study was funded by a manufacturer of resistance tests (<a href="./references#CD006495-bbs2-0003" title="CohenCJ , HuntS , SensionM , FarthingC , ConantM , JacobsonS , et al. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS (London, England)2002;16(4):579‐88. [PUBMED: 11873001] ">Cohen 2002</a>), and two did not report funding (<a href="./references#CD006495-bbs2-0006" title="GreenH , GibbDM , CompagnucciA , GiacometV , deRossiA , HarperL , et al. A randomized controlled trial of genotypic HIV drug resistance testing in HIV‐1‐infected children: the PERA (PENTA 8) trial. Antiviral Therapy2006;11(7):857‐67. [PUBMED: 17302248] ">Green 2006</a>; <a href="./references#CD006495-bbs2-0009" title="RubiniNPM , BrindeiroPA , BrindeiroRM , LlerenaCA , HertogsK , TanuriA . Clinical value of HIV‐1 genotyping in children and adolescents heavily experiences in antiretroviral therapy. XIV International AIDS Conference. Barcelona, 2002. ">Rubini 2002</a>). We judged these studies to be at high and unclear risk of bias, respectively. </p> </section> <section id="CD006495-sec-0092"> <h5 class="title">Publication bias</h5> <p>We assessed publication bias for virological failure using a funnel plot, which appeared asymmetrical on visual inspection (<a href="#CD006495-fig-0004">Figure 4</a>). We also ran Egger's regression test and confirmed this asymmetry (P &lt; 0.001) (<a href="./references#CD006495-bbs2-0048" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ (Clinical research ed.)1997;315(7109):629‐34. [PUBMED: 9310563] ">Egger 1997</a>). </p> <div class="figure" id="CD006495-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Resistance testing versus no resistance testing, outcome: 1.2 Virological failure." data-id="CD006495-fig-0004" src="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_n/nCD006495-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Resistance testing versus no resistance testing, outcome: 1.2 Virological failure. </p> </div> </div> </div> </section> </section> </section> <section id="CD006495-sec-0093"> <h3 class="title" id="CD006495-sec-0093">Effects of interventions</h3> <p>See: <a href="./full#CD006495-tbl-0001"><b>Summary of findings for the main comparison</b> Resistance testing versus no resistance testing in HIV‐positive people</a> </p> <p>See <a href="./full#CD006495-tbl-0001">summary of findings Table for the main comparison</a>. </p> <section id="CD006495-sec-0094"> <h4 class="title">Resistance testing versus no resistance testing</h4> <section id="CD006495-sec-0095"> <h5 class="title">Mortality</h5> <p>Researchers reported no differences in mortality between the group that received resistance testing and the group that did not (odds ratio (OR) 0.89, 95% CI 0.36 to 2.22; 5 trials, 1140 participants; P = 0.800; <a href="./references#CD006495-fig-0011" title="">Analysis 1.1</a>; <a href="#CD006495-fig-0005">Figure 5</a>). </p> <div class="figure" id="CD006495-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Resistance testing (RT) versus no RT, outcome: 1.1 Mortality." data-id="CD006495-fig-0005" src="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_n/nCD006495-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Resistance testing (RT) versus no RT, outcome: 1.1 Mortality.</p> </div> </div> </div> </section> <section id="CD006495-sec-0096"> <h5 class="title">Virological failure</h5> <p>Virological failure was less likely in the group that received resistance testing than in the group that did not (OR 0.70, 95% CI 0.56 to 0.87; 10 trials, 1728 participants; P &lt; 0.001; <a href="./references#CD006495-fig-0012" title="">Analysis 1.2</a>; <a href="#CD006495-fig-0006">Figure 6</a>). </p> <div class="figure" id="CD006495-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Resistance testing (RT) versus no RT, outcome: 1.2 Virological failure." data-id="CD006495-fig-0006" src="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_n/nCD006495-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Resistance testing (RT) versus no RT, outcome: 1.2 Virological failure. </p> </div> </div> </div> </section> <section id="CD006495-sec-0097"> <h5 class="title">Change in CD4 cell count</h5> <p>The change in CD4 cell count was similar in the group that received resistance testing and in the group that did not (mean difference (MD) ‐1.00 cells/mm³, 95% CI ‐12.49 to 10.50; 7 trials, 1349 participants; P = 0.860; <a href="./references#CD006495-fig-0013" title="">Analysis 1.3</a>; <a href="#CD006495-fig-0007">Figure 7</a>). </p> <div class="figure" id="CD006495-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Resistance testing (RT) versus no RT, outcome: 1.3 Change in CD4 cell count." data-id="CD006495-fig-0007" src="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_n/nCD006495-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Resistance testing (RT) versus no RT, outcome: 1.3 Change in CD4 cell count. </p> </div> </div> </div> </section> <section id="CD006495-sec-0098"> <h5 class="title">Progression to AIDS</h5> <p>Data show no differences in the proportion of participants who progressed to AIDS in the group that received resistance testing compared to the group that did not (OR 0.64, 95% CI 0.31 to 1.29; 3 trials, 809 participants; P = 0.210; <a href="./references#CD006495-fig-0014" title="">Analysis 1.4</a>; <a href="#CD006495-fig-0008">Figure 8</a>) </p> <div class="figure" id="CD006495-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Resistance testing (RT) versus no RT, outcome: 1.4 Progression to AIDS." data-id="CD006495-fig-0008" src="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_n/nCD006495-AFig-FIG08.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Resistance testing (RT) versus no RT, outcome: 1.4 Progression to AIDS. </p> </div> </div> </div> </section> <section id="CD006495-sec-0099"> <h5 class="title">Adverse events</h5> <p>Adverse events were comparable between groups (OR 0.89, 95% CI 0.51 to 1.55; 4 trials, 808 participants; P = 0.670; <a href="./references#CD006495-fig-0015" title="">Analysis 1.5</a>; <a href="#CD006495-fig-0009">Figure 9</a>). </p> <div class="figure" id="CD006495-fig-0009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 9</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Resistance testing (RT) versus no RT, outcome: 1.5 Adverse events." data-id="CD006495-fig-0009" src="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_n/nCD006495-AFig-FIG09.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Resistance testing (RT) versus no RT, outcome: 1.5 Adverse events. </p> </div> </div> </div> </section> <section id="CD006495-sec-0100"> <h5 class="title">Change in viral load</h5> <p>Change in log₁₀ viral load was greater in the group that received resistance testing (MD ‐0.23, 95% CI ‐0.35 to ‐0.11; 10 trials, 1837 participants; P &lt; 0.001; <a href="./references#CD006495-fig-0016" title="">Analysis 1.6</a>; <a href="#CD006495-fig-0010">Figure 10</a>). </p> <div class="figure" id="CD006495-fig-0010"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 10</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Resistance testing (RT) versus no RT, outcome: 1.6 Change in viral load." data-id="CD006495-fig-0010" src="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_n/nCD006495-AFig-FIG10.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Resistance testing (RT) versus no RT, outcome: 1.6 Change in viral load. </p> </div> </div> </div> <p>No studies reported on development of new opportunistic infections or on quality of life. </p> </section> <section id="CD006495-sec-0101"> <h5 class="title">Subgroup analyses</h5> <p>Statistical heterogeneity was low in all primary analyses, never exceeding I² = 25%. None of the preplanned subgroup analyses revealed any statistically significant subgroup effects for any reported outcomes. </p> <section id="CD006495-sec-0102"> <h6 class="title">Potency of ART</h6> <p>Data were insufficient to show the potency of ART as a possible effect modifier. Included studies used a wide variety of approaches to describe the potency of ART, including the impact of resistance testing on the choice of ART (<a href="./references#CD006495-bbs2-0003" title="CohenCJ , HuntS , SensionM , FarthingC , ConantM , JacobsonS , et al. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS (London, England)2002;16(4):579‐88. [PUBMED: 11873001] ">Cohen 2002</a>; <a href="./references#CD006495-bbs2-0005" title="DurantJ , ClevenberghP , HalfonP , DelgiudiceP , PorsinS , SimonetP , et al. Drug‐resistance genotyping in HIV‐1 therapy: the VIRADAPT randomised controlled trial. Lancet (London, England)1999;353(9171):2195‐9. [PUBMED: 10392984] ">Durant 1999</a>), the number of new drugs prescribed (<a href="./references#CD006495-bbs2-0001" title="BaxterJD , MayersDL , WentworthDN , NeatonJD , HooverML , WintersMA , et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS (London, England)2000;14(9):F83‐93. [PUBMED: 10894268] ">Baxter 2000</a>; <a href="./references#CD006495-bbs2-0004" title="Evaluation of Resistance Assays (ERA) Trial Investigators. A randomized controlled trial of the clinical utility of genotypic resistance testing in patients with limited prior exposure to antiretroviral drugs. HIV Clinical Trials2005;6(4):183‐6. [PUBMED: 16214734] ">Dunn 2005</a>), the number of potent drugs given (<a href="./references#CD006495-bbs2-0008" title="MeynardJL , VrayM , Morand‐JoubertL , RaceE , DescampsD , PeytavinG , et al. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS (London, England)2002;16(5):727‐36. [PUBMED: 11964529] ">Meynard 2002</a>), the proportions of participants who received potent drugs (<a href="./references#CD006495-bbs2-0007" title="HaubrichRH , KemperCA , HellmannNS , KeiserPH , WittMD , TillesJG , et al. A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575. AIDS (London, England)2005;19(3):295‐302. [PUBMED: 15718840] ">Haubrich 2005</a>), and the prevalence of drug resistance mutations (<a href="./references#CD006495-bbs2-0002" title="CingolaniA , AntinoriA , RizzoMG , MurriR , AmmassariA , BaldiniF , et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS (London, England)2002;16(3):369‐79. [PUBMED: 11834948] ">Cingolani 2002</a>). </p> </section> <section id="CD006495-sec-0103"> <h6 class="title">Type of resistance test</h6> <p>We noted no subgroup effects when we compared genotypic resistance tests to phenotypic resistance tests for the outcomes of mortality (<a href="./references#CD006495-fig-0017" title="">Analysis 2.1</a>) and virological failure (<a href="./references#CD006495-fig-0018" title="">Analysis 2.2</a>). Contrary to the pooled results, we noted no differences in virological failure in the subgroup of studies that used phenotypic tests. This is likely due to the fact that studies lacked the power needed to detect a difference among the three studies (371 participants) that used phenotypic tests. </p> </section> <section id="CD006495-sec-0104"> <h6 class="title">Use of expert advice</h6> <p>We saw no subgroup effects when we compared the addition of expert advice to resistance tests versus resistance testing alone for the outcomes of mortality (<a href="./references#CD006495-fig-0019" title="">Analysis 3.1</a>) and virological failure (<a href="./references#CD006495-fig-0020" title="">Analysis 3.2</a>). However, no difference in virological failure could be seen among studies that did not use expert advice. </p> </section> <section id="CD006495-sec-0105"> <h6 class="title">Children versus adults</h6> <p>We observed no subgroup effects when we compared trials that exclusively enrolled children or adolescents versus those that exclusively enrolled adults for the outcomes of mortality (<a href="./references#CD006495-fig-0021" title="">Analysis 4.1</a>) and virological failure (<a href="./references#CD006495-fig-0022" title="">Analysis 4.2</a>). However, studies that included children reported no differences in virological failure. </p> <p><b>Level of advancement of disease</b> </p> <p>Data were insufficient to show the potency of the level of advancement of disease as a possible effect modifier. </p> </section> </section> <section id="CD006495-sec-0106"> <h5 class="title">Sensitivity analyses</h5> <section id="CD006495-sec-0107"> <h6 class="title">Risk of bias</h6> <p>Mortality was comparable between studies at high or unclear risk of bias and those at low risk of bias (<a href="./references#CD006495-fig-0023" title="">Analysis 5.1</a>). Results show no significant differences in virological failure between studies at high or unclear risk of bias and those at low risk of bias (<a href="./references#CD006495-fig-0024" title="">Analysis 5.2</a>). </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD006495-sec-0108" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD006495-sec-0108"></div> <section id="CD006495-sec-0109"> <h3 class="title" id="CD006495-sec-0109">Summary of main results</h3> <p>See <a href="./full#CD006495-tbl-0001">summary of findings Table for the main comparison</a>. Eleven RCTs, which included 2531 participants, met the inclusion criteria of this review. All participants were experiencing failing ART (none were starting ART for the first time). We found that resistance testing probably has little or no impact on mortality (moderate‐certainty evidence) nor on progression to AIDS (moderate‐certainty evidence). Resistance testing probably may reduce the risk of virological failure (low‐certainty evidence) and reduces mean HIV viral load (moderate‐certainty evidence). It probably has little or no effect on change in CD4 cell count (moderate‐certainty evidence) nor on adverse events (low‐certainty evidence). Data show no serious inconsistency: we did not find any statistically significant heterogeneity for any outcomes, and the I² statistic ranged from 0 to 25%. Effects of resistance testing were similar by type of resistance test (genotypic versus phenotypic), the addition of expert advice to interpretation of resistance tests, and age. Results for mortality were also consistent in all subgroups. </p> </section> <section id="CD006495-sec-0110"> <h3 class="title" id="CD006495-sec-0110">Overall completeness and applicability of evidence</h3> <p>We identified literature suggesting that resistance testing may be beneficial for people with HIV who are experiencing failing ART. Findings of this Cochrane Review are dominated by data from the USA ‐ <a href="./references#CD006495-bbs2-0001" title="BaxterJD , MayersDL , WentworthDN , NeatonJD , HooverML , WintersMA , et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS (London, England)2000;14(9):F83‐93. [PUBMED: 10894268] ">Baxter 2000,</a><a href="./references#CD006495-bbs2-0003" title="CohenCJ , HuntS , SensionM , FarthingC , ConantM , JacobsonS , et al. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS (London, England)2002;16(4):579‐88. [PUBMED: 11873001] ">Cohen 2002,</a><a href="./references#CD006495-bbs2-0007" title="HaubrichRH , KemperCA , HellmannNS , KeiserPH , WittMD , TillesJG , et al. A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575. AIDS (London, England)2005;19(3):295‐302. [PUBMED: 15718840] ">Haubrich 2005,</a><a href="./references#CD006495-bbs2-0008" title="MeynardJL , VrayM , Morand‐JoubertL , RaceE , DescampsD , PeytavinG , et al. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS (London, England)2002;16(5):727‐36. [PUBMED: 11964529] ">Meynard 2002,</a><a href="./references#CD006495-bbs2-0011" title="WegnerSA , WallaceMR , AronsonNE , TaskerSA , BlazesDL , TammingaC , et al. Long‐term efficacy of routine access to antiretroviral‐resistance testing in HIV type 1‐infected patients: results of the clinical efficacy of resistance testing trial. Clinical Infectious Diseases2004;38(5):723‐30. [PUBMED: 14986258] ">Wegner 2004</a> ‐ and from other high‐income countries such as Italy (<a href="./references#CD006495-bbs2-0002" title="CingolaniA , AntinoriA , RizzoMG , MurriR , AmmassariA , BaldiniF , et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS (London, England)2002;16(3):369‐79. [PUBMED: 11834948] ">Cingolani 2002</a>), UK (<a href="./references#CD006495-bbs2-0004" title="Evaluation of Resistance Assays (ERA) Trial Investigators. A randomized controlled trial of the clinical utility of genotypic resistance testing in patients with limited prior exposure to antiretroviral drugs. HIV Clinical Trials2005;6(4):183‐6. [PUBMED: 16214734] ">Dunn 2005</a>), France (<a href="./references#CD006495-bbs2-0005" title="DurantJ , ClevenberghP , HalfonP , DelgiudiceP , PorsinS , SimonetP , et al. Drug‐resistance genotyping in HIV‐1 therapy: the VIRADAPT randomised controlled trial. Lancet (London, England)1999;353(9171):2195‐9. [PUBMED: 10392984] ">Durant 1999</a>), and Spain (<a href="./references#CD006495-bbs2-0010" title="TuralC , RuizL , HoltzerC , SchapiroJ , VicianaP , GonzalezJ , et al. Clinical utility of HIV‐1 genotyping and expert advice: the Havana trial. AIDS (London, England)2002;16(2):209‐18. [PUBMED: 11807305] ">Tural 2002</a>). One study included participants from Italy, Brazil, UK, Spain, Germany, and Portugal (<a href="./references#CD006495-bbs2-0006" title="GreenH , GibbDM , CompagnucciA , GiacometV , deRossiA , HarperL , et al. A randomized controlled trial of genotypic HIV drug resistance testing in HIV‐1‐infected children: the PERA (PENTA 8) trial. Antiviral Therapy2006;11(7):857‐67. [PUBMED: 17302248] ">Green 2006</a>). Only two studies included children (<a href="./references#CD006495-bbs2-0006" title="GreenH , GibbDM , CompagnucciA , GiacometV , deRossiA , HarperL , et al. A randomized controlled trial of genotypic HIV drug resistance testing in HIV‐1‐infected children: the PERA (PENTA 8) trial. Antiviral Therapy2006;11(7):857‐67. [PUBMED: 17302248] ">Green 2006</a>; <a href="./references#CD006495-bbs2-0009" title="RubiniNPM , BrindeiroPA , BrindeiroRM , LlerenaCA , HertogsK , TanuriA . Clinical value of HIV‐1 genotyping in children and adolescents heavily experiences in antiretroviral therapy. XIV International AIDS Conference. Barcelona, 2002. ">Rubini 2002</a>). No studies included treatment‐naive people living with HIV. Therefore, data from low‐income countries and on children and people initiating therapy are lacking. We note that all of these trials were conducted more than 10 years ago, and findings from this review should be interpreted with the understanding that novel antiretroviral drugs lead to more favourable outcomes in patients whose treatment is not informed by a resistance test. Integrase strand inhibitors, especially dolutegravir and bictegravir, are much more potent and have a higher barrier to resistance when compared with most of the non‐nucleoside reverse transcriptase inhibitors (NNRTIs) and early‐generation protease inhibitors (e.g. lopinavir) that were used in the RCTs included in this review (<a href="./references#CD006495-bbs2-0078" title="TsiangM , JonesGS , GoldsmithJ , MulatoA , HansenD , KanE , et al. Antiviral activity of bictegravir (GS‐9883), a novel potent HIV‐1 integrase strand transfer Inhibitor with an improved resistance profile. Antimicrobial Agents and Chemotherapy2016;60(12):7086‐97. [PUBMED: 27645238] ">Tsiang 2016</a>). Thus, whether or not resistance testing has a similar impact on viral outcomes among patients starting integrase inhibitor‐based regimens is speculative. Owing to limited data, we were unable to explore the role of the potency of ART in this systematic review. We also acknowledge that newer algorithms for interpreting genotypic tests may be more sensitive (<a href="./references#CD006495-bbs2-0043" title="DesaiS , KyriakidesT , HolodniyM , Al‐SalmanJ , GriffithB , KozalM . Evolution of genotypic resistance algorithms and their impact on the interpretation of clinical trials: an OPTIMA trial substudy. HIV Clinical Trials2007;8(5):293‐302. [PUBMED: 17956830] ">Desai 2007</a>), and some patients with drug resistance included in the older studies may have been missed. These facts would bias results towards the null. Length of follow‐up in many studies was less than one year (median six months). Therefore, we cannot make inferences about the long‐term effects of treatment regimens informed by resistance tests. </p> <section id="CD006495-sec-0111"> <h4 class="title">Certainty of the evidence</h4> <p>The certainty of evidence for measured outcomes ranged from low to moderate. The main methodological concern of review authors was the lack of blinding noted in included studies. Most study authors declared that studies were open‐label or did not mention blinding. Resistance testing is a complex intervention that includes laboratory technicians, the attending physician(s), and the patient. Blinding, especially of the healthcare provider, may not be possible. Based on this, we did not downgrade for blinding when examining objective outcomes such as mortality and laboratory‐based measures (viral load, CD4 cell count). Many studies did not report how the allocation sequence was generated, and we had concerns about whether the allocation process was truly random. We found evidence of publication bias for the outcome of virological failure and downgraded for this. </p> </section> </section> <section id="CD006495-sec-0112"> <h3 class="title" id="CD006495-sec-0112">Potential biases in the review process</h3> <p>We minimized biases in the review process by considering literature written in any language, by performing a comprehensive search of databases and conference proceedings, and by contacting experts in the field for unpublished and ongoing studies (as part of the consultative process for the development of World Health Organization (WHO) guidelines (<a href="./references#CD006495-bbs2-0085" title="World Health Organization. Guidelines on the Public Health Response to Pretreatment HIV Drug Resistance. http://apps.who.int/iris/bitstream/handle/10665/255880/9789241550055‐eng.pdf?sequence=1 (accessed 25 July 2018). ">WHO 2017a</a>)). We screened articles and extracted data in duplicate. Even though we searched for observational studies, we found none. The absence of validated search strategies for observational studies in HIV precludes our ability to verify whether we missed any studies. Our assessment of publication bias for virological failure through visual inspection of a funnel plot and use of Egger's test suggested the presence of publication bias. </p> </section> <section id="CD006495-sec-0113"> <h3 class="title" id="CD006495-sec-0113">Agreements and disagreements with other studies or reviews</h3> <p>Our findings are comparable with those of three other systematic reviews. <a href="./references#CD006495-bbs2-0076" title="TorreD , TambiniR . Antiretroviral drug resistance testing in patients with HIV‐1 infection: a meta‐analysis study. HIV Clinical Trials2002;3(1):1‐8. [PUBMED: 11819179] ">Torre 2002</a> found that undetectable viral load was more likely to be achieved at three months (odds ratio (OR) 1.7, 95% CI 1.3 to 2.2) and at six months (OR 1.6, 95% CI 1.2 to 2.2) if treatment was guided by genotypic or phenotypic resistance testing. This group included six trials (1471 participants) in this systematic review and found that expert guidance conferred additional benefits (OR 2.4, 95% CI 1.5 to 3.7). <a href="./references#CD006495-bbs2-0049" title="EnaJ , Ruiz de ApodacaRF , AmadorC , BenitoC , PasquauF . Net benefits of resistance testing directed therapy compared with standard of care in HIV‐infected patients with virological failure: a meta‐analysis. Enfermedades Infecciosas y Microbiologia Clinica2006;24(4):232‐7. [PUBMED: 16725082] ">Ena 2006</a> included eight trials (1810 participants) and reported similar findings, with better virological success achieved with genotypic or phenotypic resistance testing (risk ratio (RR) 1.23, 95% CI 1.09 to 1.40) and better expert interpretation provided (RR 1.82, 95% CI 1.38 to 2.40). <a href="./references#CD006495-bbs2-0062" title="PanidouET , TrikalinosTA , IoannidisJP . Limited benefit of antiretroviral resistance testing in treatment‐experienced patients: a meta‐analysis. AIDS (London, England)2004;18(16):2153‐61. [PUBMED: 15577648] ">Panidou 2004</a>, which included 10 trials (2258 participants), found that genotypic resistance testing increased the proportions of participants with undetectable viral load at three months by 11% (95% CI 6 to 16) and at six months by 10% (95% CI 5 to 16). All three systematic reviews focused on people who were experiencing failing treatment. We found no subgroup effects for expert advice, even though virological failure appeared to be less likely with expert advice (expert advice: OR 0.59, 95% CI 0.41 to 0.83; no expert advice: OR 0.77, 95% CI 0.57 to 1.04). </p> <p>Minor differences between the findings of our review and of these three reviews may be explained by the number of included studies and the inclusion criteria applied. We found 11 trials, whereas the largest of the previous reviews included only 10 studies (<a href="./references#CD006495-bbs2-0062" title="PanidouET , TrikalinosTA , IoannidisJP . Limited benefit of antiretroviral resistance testing in treatment‐experienced patients: a meta‐analysis. AIDS (London, England)2004;18(16):2153‐61. [PUBMED: 15577648] ">Panidou 2004</a>). In addition, authors of these three reviews explored head‐to‐head comparisons of different resistance tests (<a href="./references#CD006495-bbs2-0062" title="PanidouET , TrikalinosTA , IoannidisJP . Limited benefit of antiretroviral resistance testing in treatment‐experienced patients: a meta‐analysis. AIDS (London, England)2004;18(16):2153‐61. [PUBMED: 15577648] ">Panidou 2004</a>). </p> <p>Even though we sought to include data on treatment‐naive patients initiating therapy, we found no relevant studies. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD006495-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/urn:x-wiley:14651858:media:CD006495:CD006495-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_t/tCD006495-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="PRISMA study flow diagram." data-id="CD006495-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_n/nCD006495-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>PRISMA study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/full#CD006495-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_n/nCD006495-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006495-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/urn:x-wiley:14651858:media:CD006495:CD006495-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_t/tCD006495-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="‘Risk of bias' summary: review authors' judgements about each ‘Risk of bias' item for each included study." data-id="CD006495-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_n/nCD006495-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>‘Risk of bias' summary: review authors' judgements about each ‘Risk of bias' item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/full#CD006495-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_n/nCD006495-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006495-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/urn:x-wiley:14651858:media:CD006495:CD006495-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_t/tCD006495-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="‘Risk of bias' graph: review authors' judgements about each ‘Risk of bias' item presented as percentages across all included studies." data-id="CD006495-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_n/nCD006495-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>‘Risk of bias' graph: review authors' judgements about each ‘Risk of bias' item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/full#CD006495-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_n/nCD006495-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006495-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/urn:x-wiley:14651858:media:CD006495:CD006495-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_t/tCD006495-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Resistance testing versus no resistance testing, outcome: 1.2 Virological failure." data-id="CD006495-fig-0004" src="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_n/nCD006495-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Resistance testing versus no resistance testing, outcome: 1.2 Virological failure. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/full#CD006495-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_n/nCD006495-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006495-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/urn:x-wiley:14651858:media:CD006495:CD006495-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_t/tCD006495-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Resistance testing (RT) versus no RT, outcome: 1.1 Mortality." data-id="CD006495-fig-0005" src="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_n/nCD006495-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Resistance testing (RT) versus no RT, outcome: 1.1 Mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/full#CD006495-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_n/nCD006495-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006495-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/urn:x-wiley:14651858:media:CD006495:CD006495-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_t/tCD006495-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Resistance testing (RT) versus no RT, outcome: 1.2 Virological failure." data-id="CD006495-fig-0006" src="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_n/nCD006495-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Resistance testing (RT) versus no RT, outcome: 1.2 Virological failure. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/full#CD006495-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_n/nCD006495-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006495-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/urn:x-wiley:14651858:media:CD006495:CD006495-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_t/tCD006495-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Resistance testing (RT) versus no RT, outcome: 1.3 Change in CD4 cell count." data-id="CD006495-fig-0007" src="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_n/nCD006495-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Resistance testing (RT) versus no RT, outcome: 1.3 Change in CD4 cell count. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/full#CD006495-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_n/nCD006495-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006495-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/urn:x-wiley:14651858:media:CD006495:CD006495-AFig-FIG08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_t/tCD006495-AFig-FIG08.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Resistance testing (RT) versus no RT, outcome: 1.4 Progression to AIDS." data-id="CD006495-fig-0008" src="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_n/nCD006495-AFig-FIG08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Resistance testing (RT) versus no RT, outcome: 1.4 Progression to AIDS. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/full#CD006495-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_n/nCD006495-AFig-FIG08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006495-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/urn:x-wiley:14651858:media:CD006495:CD006495-AFig-FIG09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_t/tCD006495-AFig-FIG09.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Resistance testing (RT) versus no RT, outcome: 1.5 Adverse events." data-id="CD006495-fig-0009" src="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_n/nCD006495-AFig-FIG09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Resistance testing (RT) versus no RT, outcome: 1.5 Adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/full#CD006495-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_n/nCD006495-AFig-FIG09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006495-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/urn:x-wiley:14651858:media:CD006495:CD006495-AFig-FIG10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_t/tCD006495-AFig-FIG10.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Resistance testing (RT) versus no RT, outcome: 1.6 Change in viral load." data-id="CD006495-fig-0010" src="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_n/nCD006495-AFig-FIG10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 10</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Resistance testing (RT) versus no RT, outcome: 1.6 Change in viral load. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/full#CD006495-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_n/nCD006495-AFig-FIG10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006495-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/urn:x-wiley:14651858:media:CD006495:CD006495-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_t/tCD006495-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Resistance testing (RT) versus no RT, Outcome 1 Mortality." data-id="CD006495-fig-0011" src="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_n/nCD006495-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Resistance testing (RT) versus no RT, Outcome 1 Mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/references#CD006495-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_n/nCD006495-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006495-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/urn:x-wiley:14651858:media:CD006495:CD006495-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_t/tCD006495-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Resistance testing (RT) versus no RT, Outcome 2 Virological failure." data-id="CD006495-fig-0012" src="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_n/nCD006495-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Resistance testing (RT) versus no RT, Outcome 2 Virological failure.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/references#CD006495-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_n/nCD006495-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006495-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/urn:x-wiley:14651858:media:CD006495:CD006495-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_t/tCD006495-CMP-001-03.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Resistance testing (RT) versus no RT, Outcome 3 Change in CD4 cell count." data-id="CD006495-fig-0013" src="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_n/nCD006495-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Resistance testing (RT) versus no RT, Outcome 3 Change in CD4 cell count.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/references#CD006495-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_n/nCD006495-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006495-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/urn:x-wiley:14651858:media:CD006495:CD006495-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_t/tCD006495-CMP-001-04.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Resistance testing (RT) versus no RT, Outcome 4 Progression to AIDS." data-id="CD006495-fig-0014" src="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_n/nCD006495-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Resistance testing (RT) versus no RT, Outcome 4 Progression to AIDS.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/references#CD006495-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_n/nCD006495-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006495-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/urn:x-wiley:14651858:media:CD006495:CD006495-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_t/tCD006495-CMP-001-05.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Resistance testing (RT) versus no RT, Outcome 5 Adverse events." data-id="CD006495-fig-0015" src="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_n/nCD006495-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Resistance testing (RT) versus no RT, Outcome 5 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/references#CD006495-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_n/nCD006495-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006495-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/urn:x-wiley:14651858:media:CD006495:CD006495-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_t/tCD006495-CMP-001-06.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Resistance testing (RT) versus no RT, Outcome 6 Change in viral load." data-id="CD006495-fig-0016" src="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_n/nCD006495-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Resistance testing (RT) versus no RT, Outcome 6 Change in viral load.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/references#CD006495-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_n/nCD006495-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006495-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/urn:x-wiley:14651858:media:CD006495:CD006495-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_t/tCD006495-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 RT versus no RT: subgroup analyses for type of RT, Outcome 1 Mortality." data-id="CD006495-fig-0017" src="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_n/nCD006495-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 RT versus no RT: subgroup analyses for type of RT, Outcome 1 Mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/references#CD006495-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_n/nCD006495-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006495-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/urn:x-wiley:14651858:media:CD006495:CD006495-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_t/tCD006495-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 RT versus no RT: subgroup analyses for type of RT, Outcome 2 Virological failure." data-id="CD006495-fig-0018" src="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_n/nCD006495-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 RT versus no RT: subgroup analyses for type of RT, Outcome 2 Virological failure. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/references#CD006495-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_n/nCD006495-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006495-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/urn:x-wiley:14651858:media:CD006495:CD006495-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_t/tCD006495-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 RT versus no RT: subgroup analyses for expert advice, Outcome 1 Mortality." data-id="CD006495-fig-0019" src="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_n/nCD006495-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 RT versus no RT: subgroup analyses for expert advice, Outcome 1 Mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/references#CD006495-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_n/nCD006495-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006495-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/urn:x-wiley:14651858:media:CD006495:CD006495-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_t/tCD006495-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 RT versus no RT: subgroup analyses for expert advice, Outcome 2 Virological failure." data-id="CD006495-fig-0020" src="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_n/nCD006495-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 RT versus no RT: subgroup analyses for expert advice, Outcome 2 Virological failure. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/references#CD006495-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_n/nCD006495-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006495-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/urn:x-wiley:14651858:media:CD006495:CD006495-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_t/tCD006495-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 RT versus no RT: subgroup analyses for age, Outcome 1 Mortality." data-id="CD006495-fig-0021" src="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_n/nCD006495-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 RT versus no RT: subgroup analyses for age, Outcome 1 Mortality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/references#CD006495-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_n/nCD006495-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006495-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/urn:x-wiley:14651858:media:CD006495:CD006495-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_t/tCD006495-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 RT versus no RT: subgroup analyses for age, Outcome 2 Virological failure." data-id="CD006495-fig-0022" src="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_n/nCD006495-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 RT versus no RT: subgroup analyses for age, Outcome 2 Virological failure.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/references#CD006495-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_n/nCD006495-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006495-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/urn:x-wiley:14651858:media:CD006495:CD006495-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_t/tCD006495-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 RT versus no RT: sensitivity analyses for risk of bias (RoB), Outcome 1 Mortality." data-id="CD006495-fig-0023" src="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_n/nCD006495-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 RT versus no RT: sensitivity analyses for risk of bias (RoB), Outcome 1 Mortality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/references#CD006495-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_n/nCD006495-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006495-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/urn:x-wiley:14651858:media:CD006495:CD006495-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_t/tCD006495-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 RT versus no RT: sensitivity analyses for risk of bias (RoB), Outcome 2 Virological failure." data-id="CD006495-fig-0024" src="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_n/nCD006495-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 RT versus no RT: sensitivity analyses for risk of bias (RoB), Outcome 2 Virological failure. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/references#CD006495-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/media/CDSR/CD006495/image_n/nCD006495-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD006495-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Resistance testing versus no resistance testing in HIV‐positive people</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Resistance testing versus no resistance testing in HIV‐positive people</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> HIV‐positive people<br/> <b>Setting:</b> all settings<br/> <b>Intervention:</b> resistance testing<br/> <b>Comparison:</b> no resistance testing </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (trials)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no resistance testing</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with resistance testing</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mortality</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.89<br/> (0.36 to 2.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1140<br/> (5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a,b,c</sup> </p> <p><i>Due to imprecision</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Resistance testing probably has little or no impact on mortality</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000<br/> (8 to 47) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Virological failure</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.70<br/> (0.56 to 0.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1728<br/> (10 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>a,d,e,f</sup> </p> <p><i>Due to risk of bias and publication bias</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Resistance testing may reduce the risk of virological failure</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>660 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>576 per 1000<br/> (521 to 628) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in CD4 cell count</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change in CD4 cell count was 0.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 1 lower<br/> (12.49 lower to 10.5 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1349<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a,d</sup> </p> <p><i>Due to risk of bias</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Resistance testing probably has little or no effect on change in CD4 cell count</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Progression to AIDS</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.64<br/> (0.31 to 1.29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>809<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>g</sup> </p> <p><i>Due to indirectness</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Resistance testing probably has little or no impact on progression to AIDS</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>67 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>44 per 1000<br/> (22 to 85) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.89<br/> (0.51 to 1.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>808<br/> (4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>h,i</sup> </p> <p><i>Due to risk of bias and indirectness</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Resistance testing may have little or no effect on adverse effects</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>74 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>66 per 1000<br/> (39 to 110) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Change in viral load</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Mean change in viral load was 0.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.23 lower<br/> (0.35 lower to 0.11 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1837<br/> (10 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>a,j</sup> </p> <p><i>Due to risk of bias</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Resistance testing probably results in a lower viral load</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>New opportunistic infection ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> Abbreviations: CI: confidence interval; MD: mean difference; OR: odds ratio; RCT: randomized controlled trial </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Risk of bias: all studies included for this outcome were not blinded, but we did not downgrade for this, as lack of blinding is unlikely to introduce bias.<br/> <sup>b</sup>Risk of bias: one included study was at high risk of bias overall, but it contributed 16.1% of the data (<a href="./references#CD006495-bbs2-0011" title="WegnerSA , WallaceMR , AronsonNE , TaskerSA , BlazesDL , TammingaC , et al. Long‐term efficacy of routine access to antiretroviral‐resistance testing in HIV type 1‐infected patients: results of the clinical efficacy of resistance testing trial. Clinical Infectious Diseases2004;38(5):723‐30. [PUBMED: 14986258] ">Wegner 2004</a>). We did not downgrade for this.<br/> <sup>c</sup>Downgraded by 1 for imprecision: CIs for the odds ratio include considerable harm and considerable benefit. We downgraded one point for this.<br/> <sup>d</sup>Downgraded by 1 for risk of bias: four of the included studies (˜ 37% of data) were at high or unclear risk of bias (<a href="./references#CD006495-bbs2-0002" title="CingolaniA , AntinoriA , RizzoMG , MurriR , AmmassariA , BaldiniF , et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS (London, England)2002;16(3):369‐79. [PUBMED: 11834948] ">Cingolani 2002;</a><a href="./references#CD006495-bbs2-0003" title="CohenCJ , HuntS , SensionM , FarthingC , ConantM , JacobsonS , et al. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS (London, England)2002;16(4):579‐88. [PUBMED: 11873001] ">Cohen 2002;</a><a href="./references#CD006495-bbs2-0007" title="HaubrichRH , KemperCA , HellmannNS , KeiserPH , WittMD , TillesJG , et al. A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575. AIDS (London, England)2005;19(3):295‐302. [PUBMED: 15718840] ">Haubrich 2005;</a><a href="./references#CD006495-bbs2-0009" title="RubiniNPM , BrindeiroPA , BrindeiroRM , LlerenaCA , HertogsK , TanuriA . Clinical value of HIV‐1 genotyping in children and adolescents heavily experiences in antiretroviral therapy. XIV International AIDS Conference. Barcelona, 2002. ">Rubini 2002</a>).<br/> <sup>e</sup>Indirectness: the included studies used different cutoffs to define virological failure. We did not downgrade for this.<br/> <sup>f</sup>Downgraded by 1 for publication bias: based on funnel plot asymmetry and a positive Egger's test.<br/> <sup>g</sup>Downgraded by 1 for indirectness: "progression to AIDS" was not defined uniformly across studies.<br/> <sup>h</sup>Downgraded by 1 for risk of bias: all studies included for this outcome were not blinded and adverse events could be interpreted subjectively.<br/> <sup>i</sup>Downgraded by 1 for indirectness: "adverse event" was not defined uniformly across studies. We downgraded one point for this.<br/> <sup>j</sup>Downgraded by 1 for risk of bias: four of the included studies (˜ 34% of data) were at high or unclear risk of bias (<a href="./references#CD006495-bbs2-0002" title="CingolaniA , AntinoriA , RizzoMG , MurriR , AmmassariA , BaldiniF , et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS (London, England)2002;16(3):369‐79. [PUBMED: 11834948] ">Cingolani 2002;</a><a href="./references#CD006495-bbs2-0003" title="CohenCJ , HuntS , SensionM , FarthingC , ConantM , JacobsonS , et al. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS (London, England)2002;16(4):579‐88. [PUBMED: 11873001] ">Cohen 2002;</a><a href="./references#CD006495-bbs2-0007" title="HaubrichRH , KemperCA , HellmannNS , KeiserPH , WittMD , TillesJG , et al. A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575. AIDS (London, England)2005;19(3):295‐302. [PUBMED: 15718840] ">Haubrich 2005;</a><a href="./references#CD006495-bbs2-0009" title="RubiniNPM , BrindeiroPA , BrindeiroRM , LlerenaCA , HertogsK , TanuriA . Clinical value of HIV‐1 genotyping in children and adolescents heavily experiences in antiretroviral therapy. XIV International AIDS Conference. Barcelona, 2002. ">Rubini 2002</a>). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Resistance testing versus no resistance testing in HIV‐positive people</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/full#CD006495-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD006495-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Additional characteristics of included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Trial ID (acronym)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Location</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Exposure criteria</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Definition of virological failure at entry</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Type of resistance testing compared to control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Primary virological success cutoff point (copies/mL)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Expert opinion</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duration of follow‐up (weeks)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006495-bbs2-0001" title="BaxterJD , MayersDL , WentworthDN , NeatonJD , HooverML , WintersMA , et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS (London, England)2000;14(9):F83‐93. [PUBMED: 10894268] ">Baxter 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A combination antiretroviral regimen containing a single PI (indinavir, nelfinavir, saquinavir, or </p> <p>ritonavir) and 2 NRTIs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Four conditions: (1) patient taking a current triple‐drug regimen for at least 16 weeks; (2) a locally determined screening HIV‐1‐RNA level &gt; 20,000 copies/mL by the Roche Amplicor HIV‐1 assay or &gt; 10,000 copies/mL by the Chiron branched chain (bDNA) assay within 6 weeks before a required baseline visit; (3) documentation that the screening HIV‐1‐RNA level was 3‐fold greater than the nadir HIV‐1‐RNA level while on the triple‐drug regimen, or that the nadir was &lt; 500 copies/mL; and (4) a centrally determined HIV‐1‐RNA level &gt; 5000 copies/mL by the Chiron 2.0 bDNA assay using plasma collected at the baseline visit </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Genotype</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006495-bbs2-0002" title="CingolaniA , AntinoriA , RizzoMG , MurriR , AmmassariA , BaldiniF , et al. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS (London, England)2002;16(3):369‐79. [PUBMED: 11834948] ">Cingolani 2002</a> (ARGENTA) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At least 2 months on a highly active</p> <p>antiretroviral regimen</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Two conditions: (1) plasma viral load &gt; 2000 copies/mL in at least two consecutive determinations; or (2) &lt; 1 log reduction in HIV RNA more than 2 months after the start of the last regimen </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Genotype</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006495-bbs2-0003" title="CohenCJ , HuntS , SensionM , FarthingC , ConantM , JacobsonS , et al. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS (London, England)2002;16(4):579‐88. [PUBMED: 11873001] ">Cohen 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At least 2 NRTIs and only one PI, taken for at least</p> <p>1 month before screening</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV‐1‐RNA plasma levels ≥ 2000 copies/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phenotype</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006495-bbs2-0004" title="Evaluation of Resistance Assays (ERA) Trial Investigators. A randomized controlled trial of the clinical utility of genotypic resistance testing in patients with limited prior exposure to antiretroviral drugs. HIV Clinical Trials2005;6(4):183‐6. [PUBMED: 16214734] ">Dunn 2005</a> (ERA) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>On ART</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Most recent HIV‐1‐RNA plasma viral load (VL) exceeding 2000 copies/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Genotype</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006495-bbs2-0005" title="DurantJ , ClevenberghP , HalfonP , DelgiudiceP , PorsinS , SimonetP , et al. Drug‐resistance genotyping in HIV‐1 therapy: the VIRADAPT randomised controlled trial. Lancet (London, England)1999;353(9171):2195‐9. [PUBMED: 10392984] ">Durant 1999</a> (VIRADAPT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>France</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At least 6 months of treatment with nucleoside</p> <p>analogues and at least 3 months of treatment with a protease</p> <p>inhibitor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Plasma HIV‐1‐RNA &gt; 10,000 copies/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Genotype</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006495-bbs2-0006" title="GreenH , GibbDM , CompagnucciA , GiacometV , deRossiA , HarperL , et al. A randomized controlled trial of genotypic HIV drug resistance testing in HIV‐1‐infected children: the PERA (PENTA 8) trial. Antiviral Therapy2006;11(7):857‐67. [PUBMED: 17302248] ">Green 2006</a> (PERA (PENTA 8)) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Italy, Brazil, UK, Spain, Germany, Portugal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Greater exposure than 2 or 3 nucleoside reverse</p> <p>transcriptase inhibitors (NRTIs) for &lt; 2 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Most recent HIV‐1‐RNA plasma viral load &gt; 2000 copies/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Genotype</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006495-bbs2-0007" title="HaubrichRH , KemperCA , HellmannNS , KeiserPH , WittMD , TillesJG , et al. A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575. AIDS (London, England)2005;19(3):295‐302. [PUBMED: 15718840] ">Haubrich 2005</a> (CCTG) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At least</p> <p>6 months of previous ART, exposure to no more than</p> <p>2 prior protease inhibitors (PIs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HIV RNA &gt; 400 copies/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phenotype</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006495-bbs2-0008" title="MeynardJL , VrayM , Morand‐JoubertL , RaceE , DescampsD , PeytavinG , et al. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS (London, England)2002;16(5):727‐36. [PUBMED: 11964529] ">Meynard 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Previous exposure to at least 1 protease inhibitor (PI)</p> <p>for at least 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Plasma HIV‐1‐RNA &gt; 1000 copies/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Genotype and Phenotype</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006495-bbs2-0009" title="RubiniNPM , BrindeiroPA , BrindeiroRM , LlerenaCA , HertogsK , TanuriA . Clinical value of HIV‐1 genotyping in children and adolescents heavily experiences in antiretroviral therapy. XIV International AIDS Conference. Barcelona, 2002. ">Rubini 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Brazil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Previous exposure to at least 2 ART regimens, with failure of their current therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Genotype</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006495-bbs2-0010" title="TuralC , RuizL , HoltzerC , SchapiroJ , VicianaP , GonzalezJ , et al. Clinical utility of HIV‐1 genotyping and expert advice: the Havana trial. AIDS (London, England)2002;16(2):209‐18. [PUBMED: 11807305] ">Tural 2002</a> (Havana) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Spain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stable antiretroviral</p> <p>therapy combination for longer than 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Plasma HIV‐1‐RNA ≥ 1000 copies/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Genotype</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 400</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD006495-bbs2-0011" title="WegnerSA , WallaceMR , AronsonNE , TaskerSA , BlazesDL , TammingaC , et al. Long‐term efficacy of routine access to antiretroviral‐resistance testing in HIV type 1‐infected patients: results of the clinical efficacy of resistance testing trial. Clinical Infectious Diseases2004;38(5):723‐30. [PUBMED: 14986258] ">Wegner 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Receiving a</p> <p>stable ART regimen containing ≥ 2 drugs for at least 8 weeks</p> <p>before randomization</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>VL &gt; 3.0 log₁₀ copies/mL concomitant with ≥ 1 of the following conditions: &lt; 1.0 log₁₀ reduction in VL 4 weeks after start of a therapy regimen, failure to suppress VL to &lt; 200 copies/mL 6 weeks after start of therapy, detection of plasma VL &gt; 3.0 log₁₀ copies/mL after initial suppression to &lt; 200 copies/mL, or increase of &gt; 0.5 log₁₀ copies/mL (to &gt; 3.0 log₁₀ copies/mL) from the nadir VL that could not be directly attributed to vaccination or intercurrent illness </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Genotype and Phenotype</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>Abbreviations: ART: antiretroviral therapy; bDNA: branched DNA assay; NA: not applicable; NRTI: nucleoside reverse transcriptase inhibitor; PI: protease inhibitor; VL: viral load. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Additional characteristics of included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/full#CD006495-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006495-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Resistance testing (RT) versus no RT</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.36, 2.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Virological failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1728</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.56, 0.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Change in CD4 cell count <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1349</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [‐12.49, 10.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Progression to AIDS <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>809</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.31, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>808</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.51, 1.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Change in viral load <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1837</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.23 [‐0.35, ‐0.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Resistance testing (RT) versus no RT</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/references#CD006495-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006495-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">RT versus no RT: subgroup analyses for type of RT</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1537</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.37, 1.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Genotype</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>890</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.33, 2.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Phenotype</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>647</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.14, 5.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Virological failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1601</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.55, 0.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Genotype</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1230</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.52, 0.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Phenotype</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>371</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.45, 1.17]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">RT versus no RT: subgroup analyses for type of RT</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/references#CD006495-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006495-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">RT versus no RT: subgroup analyses for expert advice</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.36, 2.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Expert advice</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.06, 15.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 No expert advice</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>987</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.33, 2.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Virological failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1728</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.56, 0.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Expert advice</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>600</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.41, 0.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 No expert advice</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1128</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.57, 1.04]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">RT versus no RT: subgroup analyses for expert advice</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/references#CD006495-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006495-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">RT versus no RT: subgroup analyses for age</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.36, 2.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>164</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.16, 3.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>976</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.99 [0.31, 3.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Virological failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1728</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.56, 0.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>209</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.56, 1.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1519</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.52, 0.84]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">RT versus no RT: subgroup analyses for age</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/references#CD006495-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD006495-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">RT versus no RT: sensitivity analyses for risk of bias (RoB)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Low RoB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>945</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.30, 2.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 High or unclear RoB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>195</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [0.13, 12.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Virological failure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Low RoB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.47, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 High or unclear RoB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>622</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.55, 1.07]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">RT versus no RT: sensitivity analyses for risk of bias (RoB)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006495.pub5/references#CD006495-tbl-0007">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD006495.pub5&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD006495-note-0007">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD006495-note-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD006495-note-0006">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD006495-note-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD006495-note-0004">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD006495-note-0003">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006495\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006495\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006495\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006495\x2epub5"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006495\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006495\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006495\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006495\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006495\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006495\x2epub5"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006495\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006495\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006495\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006495\x2epub5"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006495\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006495\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006495\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006495\x2epub5"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=IregKd2C&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006495.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006495.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD006495.pub5/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD006495.pub5/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006495.pub5%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740729306416"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006495.pub5/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740729306420"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006495.pub5/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ed9aa5a77f4a4',t:'MTc0MDcyOTMwNi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 